














The Development of an Inducible Akt as a Potential Gene Therapy for 















Submitted in partial fulfillment of the 
requirements for the degree of  
Doctor of Philosophy 
















































All rights reserved 
ABSTRACT 
The Development of an Inducible Akt System as a Therapeutic Tool in Parkinson’s Disease 
Soyeon Park 
  
 Parkinson’s disease remains a major neurodegenerative disease with prevalence that is 
second only to Alzheimer’s disease. Despite much advancement in the understanding of the 
pathogenesis of Parkinson’s disease, current therapeutic options are limited to those that are only 
symptomatic and are not disease-modifying. Furthermore, due to what seems to be increasingly 
complex underlying mechanisms of the disease, identifying a broadly applicable therapeutic 
strategy is difficult. 
 There is much evidence surrounding the role of apoptosis and conversely, dysfunction of 
anti-apoptotic signaling in the progressive neurodegeneration that causes Parkinson’s disease. In 
particular, suppressed PI3K signaling has been implicated in the literature as a key event that 
occurs during neurodegeneration. Thus, regardless of the diverse upstream mechanisms that may 
lead to the disease, targeting a downstream effector of neuronal survival presents a therapeutic 
strategy that may be broadly effective against Parkinson’s disease. 
 For this dissertation, we have developed a method to control the levels of active Akt, the 
main mediator of the PI3K signaling pathway, using an innovative protein destabilizing 
technique to create an inducible Akt, DD-Akt(E40K). This method permits the control of active 
Akt levels through a commonly used and blood-brain barrier permeable antibiotic, 
Trimethoprim.  
 We have successfully established the inducibility of DD-Akt(E40K) across various 
cellular contexts, including neuronal cell types and conditions with suppressed PI3K signaling. 
This inducibility was found to be dose-responsive to Trimethoprim, reversible, and able to 
induce a known downstream substrate, FoxO4, that is an important regulator of cell survival. 
 Importantly, DD-Akt(E40K) was found to inducibly protect neuronal PC12 cells against 
Parkinson’s disease mimetic toxins as well as growth-factor removal, indicating a proof of 
principle for the targeting of Akt activity as a protective strategy against Parkinson’s disease. 
The reported trophic effects of active Akt were also corroborated using our inducible DD-
Akt(E40K) system in vivo, demonstrating significant increases in neuronal cell size within the 
substantia nigra of mice. 
 Intriguingly, the inducibility of DD-Akt(E40K) was found to be dependent on the region 
of expression in the brain of mice such that the levels of this protective protein were not 
controllable by Trimethoprim in the substantia nigra but were controllable in the striatum.  
 Taken together, the studies presented in this dissertation establish a new tool for the study 
of Akt signaling in various cellular and disease contexts and validate Akt as a promising 
therapeutic target in Parkinson’s disease. Our results also suggest an intriguing mechanism for 
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Chapter 1: General Introduction 
1.1:  Parkinson’s Disease 
 Etiology and Pathogenesis 
 Parkinson’s disease (PD) is the second most common progressive neurodegenerative 
disease, affecting 2-3% of the population ages 65 and older [1]. The principal risk factor for PD 
is considered to be increasing age, with incidence of PD being rare before 50 years of life but 
increasing 5-10 fold between ages 60-90 [2-4]. Typically thought of as a movement disorder, 
clinical diagnosis currently includes identification of cardinal motor symptoms such as tremor at 
rest, rigidity of limbs, slowness of movement or “bradykinesia”, and postural instability, along 
with responsiveness to levodopa. However, a majority of PD patients also experience a variety of 
non-motor symptoms including sleep-wake cycle dysfunction, cognitive impairment, mood 
disorders, autonomic dysfunction, and hyposmia [5] .  
 Hallmark pathological features of PD include the loss of dopaminergic neurons within the 
substantia nigra pars compacta (SNpc) and deposition of α-synuclein in the form of Lewy bodies 
and neurites [6, 7]. Although neither of these features are unique to PD, the combination of both 
is still currently used for conclusive diagnosis of idiopathic PD [1, 7].  
Dopaminergic degeneration within the SNpc is progressive and leads to subsequent loss 
of dopaminergic signaling within the nigrostriatal pathway, manifesting as the cardinal motor 
symptoms of the disease. The progression of this degeneration is reported to begin with loss of 
axonal projections and progress to death of SNpc dopaminergic neurons such that by the time of 
disease onset or diagnosis, it is believed that there has been approximately 50-60% loss of 
dopaminergic terminals within the striatum and 30% loss of SN dopaminergic neurons [8]. In 
addition to loss of dopaminergic innervation to the striatum, there are reports of degenerative 
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loss in other regions, including the peripheral nervous system, which often correlate with non-
motor symptoms of the disease. For instance, degeneration of postganglionic sympathetic 
neurons that innervate the heart has been reported in patients that exhibit orthostatic hypotension 
[9]. Similarly, drastic loss of dopaminergic enteric neurons within the myenteric plexus is widely 
believed to underlie symptoms of gastrointestinal dysfunction, such as constipation [10, 11]. 
There also exist reports of neuronal loss within the central nervous system outside of the SN, 
often correlating with the presence of high neuromelanin levels [12]. These regions of 
degeneration include the cholinergic neurons within the dorsal motor nucleus of the vagus, 
noradrenergic neurons of the locus ceruleus (LC), serotonergic neurons of the raphe nuclei, and 
cholinergic neurons of the nucleus basalis of Meynert [12]. As mentioned above, although 
various areas within the peripheral and central nervous system may exhibit neurodegeneration in 
PD, neuronal loss in the SNpc remains the defining pathological feature of PD and thus is 
exhibited in nearly all PD patients. Interestingly, loss of noradrenergic neurons within the LC 
also appears in all PD patients [12]; however, the functional significance of this is yet to be fully 
elucidated. 
The presence of abnormal intracellular protein deposits that aggregate within the SNpc 
and other brain regions affected in PD are termed Lewy bodies and Lewy neurites, collectively 
termed Lewy pathology [13, 14]. Although Lewy pathology consists of a variety of intracellular 
proteins including parkin, ubiquitin, and neurofilaments, the most abundant component is the 
protein α-synuclein [6, 15]. Initial thoughts within the field supported the belief that these 
aggregates were themselves toxic; however, more recent hypotheses suggest that Lewy 
pathology represents aggresomes that form as part of cellular processes to clear accumulation of 
misfolded proteins [16]. Although the field has not been able to fully elucidate the precise role of 
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Lewy pathology or α-synuclein in the disease, nor conclusively validate any causal role of Lewy 
pathology in disease etiology, research studies have provided insight into potential physiological 
functions and corresponding dysfunctions of α-synuclein within PD. These include evidence of 
α-synuclein involvement with synaptic dysfunction, vesicular release, axonal transport deficits, 
and ER-Golgi stress [17-25]. In further support of the hypothesis that α-synuclein dysfunction 
plays a role in the disease, studies have found that duplication or triplication in the α-synuclein 
gene can also lead to familial PD [26].  
An interesting paradigm that has been the cause of scientific debate within the field is the 
potential prion-like behavior of α-synuclein. Traditional Braak staging of the neuropathological 
changes in PD has suggested that there is pathological spreading of α-synuclein aggregates that 
begins in the lower brain stem and olfactory bulb and eventually spreads to areas of the 
midbrain, including the SNpc, finally reaching the basal forebrain and neocortex. Furthermore, 
this spread of α-synuclein pathology has also been suggested to correlate with disease 
progression [13]. However, this scheme for Braak staging of PD is a contentious topic, with 
evidence to show that there is no correlation between Braak stage and clinical severity of PD, 
and there exist cases of aged individuals who exhibit no neurological symptoms but have brain 
synucleinopathy that would be characterized as late Braak stage [27]. Review of more recent 
literature suggests that Braak staging may in fact apply to a specific subset of PD patients with 
young onset and long disease duration, but indeed may not describe generalized PD pathogenesis 
[28]. 
Nevertheless, the prion hypothesis was first thrust into the spotlight of PD research when 
autopsy studies of patients who had received nigral neuron grafts revealed Lewy pathology 
present in the grafted neurons, thus suggesting a host-to-graft propagation of disease pathology 
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[29, 30]. Furthermore, recent research has implicated the presence of toxic α-synuclein strains in 
the form of fibrils that are capable of seeding α-synuclein pathology throughout the central 
nervous system [31]. Research surrounding the spread of α-synuclein pathology eventually led to 
the development of both in vitro and in vivo α-synuclein fibril-based PD models that demonstrate 
the spread of α-synuclein aggregation and corresponding neuronal degeneration [32-34]. In 
further support of the prion hypothesis, a recent study discovered a putative receptor that is 
sufficient for pathological transmission of α-synuclein, thus providing a mechanism for the 
potential spread of α-synuclein pathology within the disease [35].    
 The large majority of PD cases are idiopathic or sporadic, with estimates ranging from 
90-95% of all PD cases [7, 36]. The remaining 5-10% are considered to be caused by inherited 
genetic abnormalities, termed familial PD [36]. Genetic studies of such cohorts have resulted in 
the discovery of various forms of monogenic PD, the first of which was autosomal-dominant PD 
caused by mutations within the SNCA gene, encoding α-synuclein [37]. Five other monogenic 
forms of PD have since been conclusively linked to classic Mendelian PD, caused by mutations 
within LRRK2, Parkin, PINK1, DJ-1, and VPS35 [37, 38]. Additionally, there exist a number of 
genes linked to atypical forms of PD, such as ATP13A2, SYNJ1, and DNAJC6, as well as many 
reported genetic risk factors, those of note including associations with GBA and MAPT [38]. 
Combined, mutations in the six confirmed monogenic forms of classic PD only account for an 
estimated 30% of familial PD cases and 3-5% of sporadic PD cases, highlighting the complexity 
of PD etiology and importance of continued efforts to further elucidate genetic causes of PD. 
 In addition to genetic causes, there also exist various environmental factors that have 
been associated with susceptibility to PD, the most infamous of which is the synthetic neurotoxin 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP was discovered as a contaminant 
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in illicitly synthesized drugs, causing Parkinsonism in unknowing drug users in 1983 [39]. Other 
environmental risk factors of PD that have been the subject of discussion within the field include 
exposure to pesticides [40, 41], traumatic brain injury [42], and endogenous cellular factors, such 
as the loss of trophic support or the formation of endogenous toxins or reactive oxygen species 
during the metabolism of endogenous dopamine [43]. In support of the endogenous toxin 
hypothesis, there have been various reports of genetic susceptibility to PD associated with 
cytochrome P450-enzyme polymorphisms [44, 45]. Cytochrome P450 is believed to have 
potential detoxifying functions within the substantia nigra. However, further studies and meta-
analyses of this association have resulted in conflicting conclusions, making the role of 
cytochrome P450 in PD unclear [46-49]. Additionally, there have been reports of polymorphisms 
in other genes that may have functions in detoxification of metabolites, such as NAT2 encoding 
N-Acetyltransferase 2 and GSTP1 encoding Glutathione S-Transferase Pi 1, but meta-analyses of 
these associations also have led to conflicting conclusions on their significance to the disease 
[50, 51]. 
 
 Current Therapies and Treatments 
Current approved treatments for PD rely on addressing the symptoms of the disease, with 
particular emphasis on the motor symptoms, but not necessarily the mechanism or cause of 
disease. The most ubiquitous methods of treatment remain pharmacological. Of these, levodopa 
(L-3,4-dihydroxyphenylalanine), a precursor to dopamine, is most effective at alleviating the 
symptoms caused by depletion of dopaminergic signaling within the nigrostriatal pathway [52]. 
Levodopa (L-DOPA) treatments are often administered as a formulation with carbidopa, an 
inhibitor of DOPA decarboxylase, to prevent the peripheral conversion of levodopa to dopamine 
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[52]. However, L-DOPA treatment is associated with increasing motor complications with 
increasing treatment time – these include dyskinesias or motor fluctuations with L-DOPA wear-
off [53]. Alternatively, dopamine agonists can also provide efficacious motor symptom 
management in PD patients, particularly in younger patients, and have a lower risk for dyskinesia 
development [54]. 
There also exist pharmacological treatments outside of dopamine-based drugs that are 
used as alternatives or as combination therapies depending on patient needs. Anticholinergic 
medications comprise the oldest class of drugs approved for use in PD and have been shown to 
improve motor function in PD patients [55]. Additionally, the antipsychotic clozapine, although 
rarely used, has been reported to improve tremors in PD patients [56]. Amantadine, a compound 
used as an antiviral drug, has also been approved by the FDA as an antiparkinsonian drug and is 
recommended by both the International Parkinson and Movement Disorder Society and the 
European Federation of Neurological Societies as an efficacious symptomatic therapy [57, 58]. 
Finally, patients with mild motor symptoms may be prescribed monoamine oxidase type B 
inhibitors (MAOBI), such as selegiline or rasagiline, to augment L-DOPA function [52].  
In practice, multiple pharmacological drugs are often used in combination to manage 
motor symptoms for each patient. As alluded to above, some of the major complications of 
dopamine-based treatments are motor fluctuations that are triggered as the medication wears off 
as well as management of motor symptom reemergence during “off” time. Strategies to combat 
these side effects focus on methods for continuous dopaminergic stimulation. These include the 
use of MAOBIs or catechol-O-methyltransferase inhibitors (COMTIs) to inhibit the metabolism 
of dopamine [52, 59], improved sustained-release formulations of L-DOPA, as well as dopamine 
agonists as an adjunctive therapy with L-DOPA to prolong its effects and minimize “off” time. 
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In addition, amantadine has reported anti-dyskinetic effects and is also used to combat motor 
fluctuations from wear-off and dyskinesia in PD patients [60]. There also exist alternative 
delivery strategies for prolonged or rapid acting drug action such as continuous duodenal 
infusion (Duodopa), and administration of dopamine agonists through rectal, intranasal, 
sublingual, subcutaneous, and transdermal routes [61].  
 For patients who develop severe dyskinesias and motor fluctuations enough to impair 
quality of life, there also exist surgical interventions, the most common of which is deep brain 
stimulation (DBS). Pioneered as a PD therapy nearly three decades ago, DBS has been shown to 
effectively reduce levodopa-responsive symptoms, dyskinesia, and tremor [62]. In this treatment, 
an electrode to deliver stimulation is surgically placed into one of two conventional target areas: 
the subthalamic nucleus or the internal segment of the globus pallidus [63]. As with any 
treatment, there are limitations to DBS including reports of complications with targeting the 
subthalamic nucleus which may lead to increased depression and cognitive impairment [62]. An 
alternative surgical intervention that has been proposed is ablative surgery, such as pallidotomy 
and thalamotomy; however, this surgery carries additional risks that come with open-brain 
surgery and mistargeted lesions [62]. With the recent advent of high-intensity focused ultrasound 
as a surgical technique that, combined with MRI for target guidance, allows for incision-less 
lesions, lesion therapy may in the near future provide a viable alternative to DBS [64]. 
 Unfortunately, PD remains thus far an incurable disease. As the disease progresses, both 
motor and nonmotor symptoms increase in severity such that patients become less responsive to 
medication, and standard surgical interventions carry risks as discussed above [52, 62]. 
Additionally, almost all currently approved therapeutics are purely symptomatic and not disease-
modifying, with potential exceptions being MAOBIs and DBS of the subthalamic nucleus. 
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Rasagiline, a MAOBI, has shown evidence of neuroprotection in preclinical studies, but phase III 
clinical trial results were inconclusive [65]. Additional studies have suggested that subthalamic 
nucleus DBS is neuroprotective in animal models, potentially through BDNF-trkB signaling 
[66]. However, no putative neuroprotective therapy has yet been able to demonstrate clear 
benefit in clinical trials; therefore, there is much room for improved therapies for PD, 
particularly ones that may be disease-modifying.  
 
 Models of Parkinson’s Disease  
 There are a large variety of models and research tools that have been developed to study 
the pathogenesis of PD. These can be separated into two main categories: toxin models and 
genetic models. Although no one model perfectly recapitulates all features of the disease, a select 
few models have proven valuable for studying different aspects of the disease. Here, we will 
discuss the features of major PD models and their relevant advantages and disadvantages.   
 Pharmacological agents and toxins that lead to mitochondrial dysfunction have been 
widely used as classical models of PD, particularly as mitochondrial dysfunction has been 
implicated as a contributor to the accumulation of misfolded proteins and neuronal degeneration 
[7]. The two most common such models are 6-hydroxydopamine (6-OHDA) and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP).  
6-OHDA is a hydroxylated analogue of dopamine and was the first such toxin used to 
create animal models of PD. It is extensively used as a PD mimetic neurotoxin because it is 
selectively taken up by catecholaminergic neurons and causes their rapid death [67]. Although 
the complete mechanism of degeneration is unclear, oxidative stress is a major, if not main, 
component of 6-OHDA-induced death and is believed to result from disruption of mitochondrial 
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complex I [68]. 6-OHDA has been used for both in vitro and in vivo models, although it must be 
directly injected into the brain of intact animals as it is not able to cross the blood brain barrier 
[7, 68].  
MPTP was first discovered for its neurotoxic effects when young drug users developed 
Parkinsonism after having used illicitly synthesized drugs with MPTP as an unfortunate 
contaminant [39]. MPTP leads to selective degeneration of dopaminergic pathways with higher 
sensitivity to the toxin found in the SNpc than the ventral tegmental area (VTA), thus mimicking 
the specific regional pattern of degeneration seen in PD [69, 70]. MPTP can cross the blood brain 
barrier and thus can be systemically administered in animals, whereupon it is converted by 
monoamine oxidase B in astrocytes and serotonergic neurons into 1-methyl-4-phenylpyridinium 
(MPP+). MPP+ then is selectively taken up by catecholaminergic neurons and leads to 
impairment of mitochondrial respiration through the inhibition of mitochondrial complex I [68].  
The major advantages of these toxin-based models include the reproducibility and 
reliability of degeneration as well as the relevance as a PD model for oxidative stress and 
mitochondrial dysfunction. MPTP has the unique advantage among PD mimetic toxins of 
causing the formation of intraneuronal inclusions similar to Lewy bodies within monkeys [7, 71]. 
However, studies have found that these inclusions may indeed be distinct from classic Lewy 
bodies [72]. Furthermore, MPTP exhibits much decreased toxicity in rodent models, with no 
toxicity at all in the rat, thus limiting its utility as a widely usable in vivo PD model [7]. Reported 
evidence of 6-OHDA as an endogenous toxin within dopaminergic neurons presents support for 
the 6-OHDA-based model as one that may replicate certain contributory aspects of PD 
pathogenesis [73]. The 6-OHDA toxin model also allows for the use of an excellent experimental 
control in vivo due to the availability of the hemisphere contralateral to the injection site as an 
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internal control. In contrast, MPTP is a systemic toxin that would lead to degeneration in both 
hemispheres and thus lacks a suitable control within each animal. Despite the reported relevance 
of these toxin models to PD pathogenesis, it is true that they do not replicate all features of PD, 
thus creating an overarching disadvantage and is exemplified by the numerous clinical trial 
failures with therapies that had showed great potential in these models [74]. 
 Although there have been significant efforts to develop genetic models of PD based on 
major genes linked to the disease, these efforts have been met with difficulty because the 
majority of these genetic animal models lack significant degeneration within the SNpc [75]. 
Following the discovered importance of α-synuclein in the disease, various transgenic mouse 
models expressing the two major α-synuclein mutants (A53T and A30P) as well as WT human 
α-synuclein have been developed and tested. Although most of the earlier A53T and A30P 
mouse lines did not exhibit significant loss of dopaminergic cells within the SN, the use of the 
different promoters (murine Thy-1 or Pitx3) was found to induce more robust neurodegeneration 
and loss of DA release [75]. As an alternative to transgenic models, viral vectors that deliver and 
overexpress α-synuclein have been used to create rodent models that exhibit progressive 
degeneration of nigral neurons [75]. In contrast to the α-synuclein transgenic mouse models, 
virally-delivered α-synuclein models exhibited clearer pathology and dopaminergic degeneration 
[76-79]. More recently, several studies have demonstrated the use of α-synuclein fibrils in 
rodents as a model of transmissible α-synuclein pathology and progressive degeneration, 
including the development of motor deficits [32-34, 80].  
 Other mouse models based on knowledge of genetic risk factors for PD have also been 
developed, but to minimal success. Mutations of LRRK2 have been identified to cause a late-
onset autosomal dominant form of PD [81]. Corresponding LRRK2 knockout and LRRK2 
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mutant (G2019S and R1441C) mouse models have been developed but show mild to no 
neurodegeneration, pathological features of PD, or behavioral deficits [75]. An exception was 
found with a mouse model overexpressing G2019S LRRK2, which exhibits up to 20% 
degeneration of dopaminergic neurons in the SNpc, but an interesting reversal of degeneration of 
dopaminergic nerve terminals in the striatum at 19-20 months [82, 83]. Similarly, PINK1 
knockout mice do not show major abnormalities in the nigrostriatal dopaminergic pathway in 
terms of striatal signaling or SNpc degeneration, although there was detectable, age-dependent 
loss of striatal dopamine levels [84]. Knockout mouse models of parkin and DJ-1 likewise 
exhibited minor reductions in dopaminergic signaling but without loss of SNpc neurons [75]. 
Inactivation of multiple genes in double and triple knockout mouse models (parkin (-/-); DJ-1 (-
/-) or parkin (-/-); DJ-1 (-/-); PINK1 (-/-)) have also been developed but similarly exhibit no 
significant nigral degeneration [85, 86]. 
 To date, the genetic models of PD that best replicate key features of the disease are ones 
based on α-synuclein, particularly virally-based expression models or fibril-based models. There 
continues to be research into improving models based on other PD-linked genes, typically 
through experimenting with different breed backgrounds, deletions of different exons, or 
conditional knockout methods. However, the genetic models as they stand today have the major 
disadvantage of lacking utility as a research and development tool for Parkinson’s disease 
because of minimal observed specific degeneration of the nigrostriatal pathway. 
 
1.2:  PI3K/Akt Signaling 
 PI3K/Akt Overview and Activation 
With the diverse genetic, environmental, and potentially other endogenous processes 
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involved in the progression of PD, a therapy that addresses one cause may not be efficacious in 
patient populations with other risk factors or underlying causes. However, regardless of the 
initiating causes of the disease, the diverse pathways eventually converge onto classic cell death 
pathways involved in neurodegeneration. Thus, a promising therapeutic strategy may be to target 
pathways modulating neuronal survival. In particular, the PI3K pathway has been shown to be 
necessary and sufficient for growth factor-dependent survival in a variety of neuronal cell types, 
thus suggesting its potential to prevent neurodegeneration [87-90]. The main mediator of this 
PI3K pathway, the serine- threonine-directed kinase Akt (also known as protein kinase B), has 
been extensively studied and provides a potential molecular target to control neuronal survival.  
Akt was discovered through the initial isolation of a transforming murine T-cell 
lymphoma virus in 1977 from the AKR mouse strain, which was termed AKT8 as a shortened 
name for AKR Thymoma #8 [91]. This virus was found to encode an oncogene “v-Akt” in 1987 
[92], and subsequently, the cellular homolog “c-Akt” was cloned along with the protein kinase 
Bα (PKBα) and Related to A- and C-Protein Kinase α (RAC-PKα), which were found to be 
encoded by the same gene, Akt, in 1991 [93-95]. As a landmark finding in the field of PI3K 
signaling, Akt was found to be activated by various growth factors in a PI3K-dependent manner, 
thus establishing Akt as a previously unknown downstream effector of PI3K [96-98]. 
The Akt kinase belongs to the AGC kinase family, named such because it includes 
AMP/GMP kinases and protein kinase C [99]. Since its discovery, three mammalian isoforms of 
Akt have been identified: Akt1 (PKBα), Akt2 (PKBβ), and Akt3 (PKBγ), all of which are highly 
homologous but have been found to have only partially overlapping functions, contributing to the 
diverse downstream functions of Akt discussed in the next section [100]. Additionally, although 
all three isoforms are generally ubiquitously expressed, there exists differential tissue expression 
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of the isoforms. Akt1 has been found to be most highly expressed in brain, thymus, and testis as 
well as slightly lower levels found in the heart, lung, spleen, pancreas, and fat [101]. Akt2 has 
been found to be most predominantly expressed in tissues involved in insulin regulation, such as 
brown fat, skeletal muscle and liver, while Akt3 is most highly expressed in the brain, testis, 
lung, mammary gland, and fat but almost absent in other tissues [99, 101]. 
Research has elucidated much regarding the structure and function of Akt. The structure 
of Akt is comprised of 3 major domains: an N-terminal pleckstrin homology (PH) domain, a 
catalytic (kinase) domain, and a hydrophobic C-terminal tail (Figure 1.1). The primary structure 
of Akt is highly conserved across the three isoforms with slight variations in the C-terminal tail 
[102]. The PH domain is ~80% identical across the Akt isoforms and 30% identical to PH 
domains in other proteins [103]. This domain is crucial for binding of Akt to the plasma 
membrane as well as mediating protein-protein interactions [102]. Additionally, the sequence of 
the catalytic domain across the three Akt isoforms has been shown to be ~90% identical and 
closely related to other members of the AGC kinase family [103]. Finally, the hydrophobic C-
terminal tail is ~70% identical in sequence across Akt isoforms and most closely related to the 
PKC family [103].  
 
 
Canonical Akt activation begins when a trophic factor binds to receptor tyrosine kinases 
 
Figure 1.1: Akt structure  
The protein has 3 main domains: N-terminal pleckstrin 
homology (PH) domain, catalytic kinase domain, and a C-






and activates PI3K, which phosphorylates lipids at the plasma membrane to generate 
phosphatidylinositol 3,4 bisphosphate (PI3,4P2) or phosphatidylinositol 3,4,5 triphosphate (PIP3) 
[104]. These phosphorylated lipids exhibit high affinity for the PH domains of Akt as well as 
other relevant kinases such as phosphoinositide-dependent protein kinase 1 (PDK1), and thus 
lead to the recruitment of Akt to the inner surface of the membrane [96]. Membrane translocation 
of Akt and the binding of its PH domain to phospholipids leads to a conformational change in 
Akt from a “PH-in” to a “PH-out” conformation, allowing access to its kinase domain and its 
phosphorylation at two sites: Thr308 within the catalytic domain by PDK1 and Ser473 within the 
C-terminal hydrophobic domain by mammalian target of rapamycin complex 2 (mTORC2) [102, 
105]. PDK1 is also recruited to the membrane via its own PH domain following PI3K activation, 
thus bringing it into phosphorylation proximity to Akt [106]. Recent reports have suggested that 
mTORC2 may also contain a PH domain within the SIN1 component, leading to disinhibition of 
its kinase activity, although its dependency on PI3K activation is unclear [107, 108]. 
Additionally, recent findings have suggested the existence of internal PIP3 pools at the nuclear 
envelope and early endosomes, thus adding potential dimensionality to Akt activity and substrate 
specificity based on intracellular localization [109]. 
The two phosphorylation events at Thr308 and Ser473 are required for full catalytic 
activity of Akt, and phosphomimetic residues at the two sites lead to constant partial activation 
of Akt [102]. Whether the two canonical sites have distinct functions has not been fully parsed 
out; however, it has been discovered that phosphorylation of the Thr308 site will induce a 
conformational change in Akt that can enable substrate binding and stimulate enzymatic activity 
by an estimated 100-fold, whereas phosphorylation of the Ser473 site can induce activity levels 
by an additional 7 to 10-fold [106, 110-113]. In another sense, monophosphorylated Akt at the 
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Thr308 site has been estimated to be 10% as active as the fully phosphorylated kinase, meaning 
that only 10% of monophosphorylated Thr308 Akt molecules will adopt an active conformation 
[114]. However, it has also been suggested that the phosphorylation of Ser473 may be a 
prerequisite for, or enhance, the binding of PDK1 to Akt, as the phosphorylated Ser473 within 
the hydrophobic motif interacts with PDK1, bringing it into the proximity of the Thr308 site 
within Akt [110]. Additionally, the same phosphorylated hydrophobic motif is thought to double 
as a stimulator of kinase activity through stabilization of the active state and a docking site to 
mediate substrate interactions and allow for some level of substrate specificity [110, 114, 115].  
Outside of the two canonical phosphorylation sites of Akt, there also exist numerous 
other sites for post-translational modification that may help fine-tune Akt activity, cellular 
localization, and substrate specificity. These include additional phosphorylation sites, mediated 
by cell cycle proteins and mTORC2 to enhance Akt activity and GSK3α to attenuate Akt 
activity, as well as hydroxylation sites that trigger interactions with von Hippel-Lindau tumor 
suppressor protein (pVHL), acetylation of the PH domain, and glycosylation of the catalytic 
domain for further functional tuning (reviewed in [105]). 
Conversely, Akt inactivation was found to be mediated upstream by the tumor suppressor 
PTEN, a known PIP3 phosphatase [116]. Thus, PTEN essentially works in opposition to PI3K, 
removing the membrane binding site for Akt and preventing its membrane recruitment, which 
therefore prevents its phosphorylation and activation by PDK1 and mTORC2. Direct 
dephosphorylation of Akt has been found to be mediated by protein phosphatase 2A (PP2A), 
specific to the Thr308 site, and PH domain leucine-rich repeat protein phosphatases 1 and 2 




 Physiological Effects of Akt and Associated Substrates 
Once Akt has become catalytically activated through phosphorylation of Thr308 and/or 
Ser473, it can then in turn interact with over 100 reported substrates to induce various 
downstream physiological effects [117]. Since its initial discovery as an oncogene capable of 
inducing T cell lymphomas in mice through the retrovirus AKT8, much of Akt research has 
focused on its role in mediating cell growth, proliferation, and survival, particularly within the 
context of cancer [99]. However, many of these same physiological processes that are mediated 
by Akt in cancer are also relevant to neurodegenerative disease, particularly Parkinson’s disease, 
as is discussed in the following section. In this section, we will explore the major Akt roles in 
cell growth, proliferation, and apoptosis and corresponding major substrates that help mediate 
these downstream effects. 
The great number of downstream Akt substrates lend to the diversity of physiological 
effects caused by Akt activation, often through inhibition of substrate activity through the 
creation of a phosphorylated 14-3-3 binding motif [117]. Furthermore, many Akt substrates are 
involved in multiple cellular functions, which may be cell context-specific [117].  
The most well-established function of Akt is its role in mediating cell survival. This role 
is often, but not always, dependent on its negative regulation of proteins involved in promoting 
apoptosis. This includes several proapoptotic Bcl-2 family members that only contain a single 
BH3 domain, such as BAD [118], as well as inhibition of transcription factors that promote the 
expression of BH3-only proteins, such as FoxO transcription factors FoxO1, FoxO3a, and 
FoxO4 [117, 119, 120]. In both cases, phosphorylation by Akt creates a binding site for cytosolic 
sequestration protein 14-3-3, and in the case of FoxO transcription factors, causes their exit from 
the nucleus, thus blocking induction of its target proapoptotic genes [119, 120]. Additionally, the 
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first Akt substrate discovered, glycogen synthase kinase 3β (GSK3β), is known to play a central 
role in insulin and Wnt signaling, but also is involved in promoting the degradation of cell 
survival proteins MCL-1 and c-Myc [105, 121-123]. GSK3β is inhibited through 
phosphorylation at the Ser9 site by Akt and therefore leads to stabilization of aforementioned 
pro-survival proteins and promotion of cell survival [105, 117].  
A highly conserved function of Akt is its promotion of cell growth, or control of cell size 
[117]. This function is predominantly mediated through indirect activation of the mTOR 
complex 1 (mTORC1) pathway, which is known to regulate translation initiation and ribosome 
biogenesis [124]. Although Akt has been suggested to directly phosphorylate substrates 
downstream of mTORC1, such as S6K1 and eukaryotic initiation factor 4E-binding protein 1 
(4E-BP1) [117], the major mechanism of mTORC1 pathway activation is more likely through 
inhibition of factors upstream of mTORC1. For instance, tuberous sclerosis complex 2 (TSC2), a 
tumor suppressor that is a known inhibitor of mTORC1 signaling, has been shown to be inhibited 
through direct phosphorylation by Akt at multiple sites, which then allows for activation of the 
Ras-related small G protein Rheb and subsequent activation of mTORC1 [125-127]. 
Additionally, proline-rich Akt substrate of 40 kDa (PRAS40), a negative regulator of mTORC1, 
was found to be directly phosphorylated and inhibited by Akt [128, 129].  
Cell proliferation is another important downstream function of Akt, although less well 
understood than cell growth or survival, that relies on both direct and indirect actions on 
substrates important in the regulation of the cell cycle [117]. Several independent studies have 
demonstrated Akt phosphorylation of cell cycle inhibitor p27 within its nuclear localization 
signal, thus impairing its nuclear import and p27-mediated G1 arrest [130-132]. Additionally, 
Akt can indirectly regulate the expression of cell cycle proteins through inhibition of 
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transcription factors such as FoxO, as discussed above, or regulation of stability and synthesis of 
cell cycle proteins through inhibition of GSK3β, which plays a role in mediating proteasomal 
degradation of cyclin proteins [133, 134], as well as inhibition of the mTORC1 signaling 
pathway proteins TSC2 and PRAS40, which can mediate cap-dependent translation of cyclins 
[135].  
A more recent potential function of Akt is its ability to induce sprouting or growth of 
axons. Earlier studies have implicated Akt as a mediator of both neurite outgrowth as well as 
growth in the thickness of processes [136, 137]. Importantly, recent studies by our collaborator, 
Dr. Robert Burke, have established a role for Akt activity in the significant increase of 
dopaminergic nigrostriatal projections within mice, even after degeneration induced by 6-OHDA 
lesions [138, 139]. This effect is believed to be mediated by the mTOR pathway, as 
overexpression of constitutively active Rheb, an mTOR regulator, has been found to recapitulate 
the protective and regenerative effects seen with overactive Akt [139, 140]. 
 
 Akt in Parkinson’s Disease and other Neurological Disorders 
Although the initial research surrounding Akt was intensely focused on cancer, the last 
two decades of research have elucidated the crucial role of Akt for neuronal survival, as well as 
evidence for dysfunction within neurological and neurodegenerative disorders.  
First, the importance of Akt in promoting survival within the context of a neuronal cell 
type under stress conditions has been clearly demonstrated in various studies (reviewed in [141]). 
Importantly, expression of dominant-negative Akt was shown to reduce the numbers of 
dopaminergic neurons in the substantia nigra (SN) of mice while expression of a constitutively 
active form of Akt significantly reduced developmental neuron death in the SN, thus highlighting 
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the important role that Akt plays in promoting survival in the neuronal population directly 
affected in PD [142].  
The role of Akt has also been explored within the context of various neurological 
diseases. For instance, loss of activity of the isoforms Akt1 and Akt3 has been implicated in 
neuropsychiatric disorders such as schizophrenia [143, 144]. Furthermore, dysfunction of the 
signaling cascade involving PI3K-Akt-mTOR has been identified as a core cause of 
neurodevelopmental and neuropsychiatric disorders, including autism spectrum disorder, 
epilepsy, and developing brain malformations (reviewed in [145]).  
Akt dysfunction specifically within the context of neurodegenerative disorders, including 
prion disease, Alzheimer’s disease (AD), and PD, has been widely investigated, with various 
studies implicating dysregulation of the kinase as a critical “common core” event underlying the 
mechanism of degeneration. Recent research has demonstrated that the repressor element 1-
silencing transcription factor (REST), a neuroprotective factor that is lost in AD [146] and prion 
disease models [147], is correlated with downregulation of Akt-mTOR signaling [148]. Other 
studies also provide evidence for impaired Akt signaling in AD; however, these studies suggest 
that aberrant, hyperactivation of Akt signaling may be an early feature of AD and is associated 
with Aβ and tau pathology [149-151].  
Most relevant to the work presented here, PD research has demonstrated impaired or 
decreased levels of Akt signaling within the disease. Immunostaining of postmortem brains from 
patients with sporadic PD has shown significantly decreased levels of phosphorylated Akt in the 
SN compared to non-PD patients, providing direct evidence of dysfunctional Akt signaling in 
PD, [152, 153]. In addition, global gene expression analysis of isolated dopaminergic neurons 
from the SNpc of PD patients and age-matched controls revealed disrupted pathways of energy 
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metabolism and cell survival in diseased neurons, with PI3K/Akt/mTOR signaling being the 
central hub of these signaling networks [154]. A separate study exploring microRNA profiles of 
isolated dopaminergic neurons from PD brains identified miR-126 as a potentiator of 
vulnerability to neurotoxins, such as 6-OHDA, by dysregulating insulin-like growth factor/PI3K 
signaling [155]. As further supporting evidence, there have been studies demonstrating the 
specific involvement of apoptosis in the development of PD through diminished upstream 
signaling of the PI3K/Akt pathway. Studies of postmortem brains from PD patients demonstrate 
the presence of apoptosis in nigral neurons [156-158], as well as dramatically decreased levels of 
trophic factors BDNF, GDNF, and NGF within the SN of PD brains [159-161]. As Akt is a core 
mediator of apoptotic signaling, these studies implicitly suggest that dysfunction of Akt signaling 
is likely involved.  
Outside of studies using human postmortem PD brains, deficiencies in Akt signaling have 
been found in genetic models of DJ-1, parkin, and PINK1 mutations [162, 163]. Furthermore, 
although the pathogenesis of PD remains to be fully elucidated, oxidative stress has been 
suggested to play a large role in the degeneration and progression of PD [164]. In relation to this 
mechanism, studies involving oxidative stressors and PD mimetic toxins, including hydrogen 
peroxide, 6-OHDA, MPP+ in vitro, and MPTP in mice, found selective dephosphorylation of Akt 
[152, 165, 166]. Thus, a large array of evidence points to the crucial role of diminished Akt 
signaling in PD disease contexts, supporting the potential of Akt signaling as a therapeutic target. 
It is worth noting that the contrasting reports on the role of Akt in AD and PD highlight the 
complexity and potentially very distinct pathological mechanisms behind these two degenerative 
diseases, which may be related to the complex interplay between PI3K/Akt/mTOR signaling and 
autophagy in both AD and PD [167]. 
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Importantly, various studies have successfully demonstrated that directly restoring or 
elevating Akt activity may be protective in various PD and cell death models. For instance, 
virally delivered myristoylated-Akt has been shown to protect SNpc dopaminergic neurons from 
death and promote sprouting in a 6-OHDA lesioned PD mouse model [138]. Overexpression of 
constitutively active Akt(E17K) in neuronal cultures was also found to be protective against PD 
toxin insults [152]. Further linking Akt signaling to PD genetics, a study in 2012 established that 
overexpression of PINK1 can rescue C2-ceramide induced cell death through maintenance of 
Akt phosphorylation and activity [168]. Similarly, a separate study investigating DJ-1 revealed 
that the neuroprotective effects of DJ-1 against hydrogen peroxide/MPP+ in vitro and MPTP in 
vivo was dependent on Akt activity [169]. In this same study, myristoylated Akt was 
demonstrated to exhibit protective effects in vitro against hydrogen peroxide, regardless of DJ-1 
genotype. There also have been various studies demonstrating that the protective roles of 
rapamycin, Rho-associated kinase inhibition, a squamosamide derivative, and insulin-like growth 
factor 1 are attributed to activation of Akt signaling pathways in both in vitro and in vivo PD 
models [170-173]. It is noteworthy that all of these studies citing the neuroprotective capacity of 
Akt restoration utilized toxin models of PD. To our knowledge, there have been no research 
studies demonstrating neuroprotective effects of Akt in non-toxin PD models. 
Such lines of evidence support the importance of Akt signaling in neuronal survival and 
repair, particularly in the case of PD, and potentially with wider implications in neuropsychiatric 
and other neurodegenerative diseases.  
 
 Translational Approaches to Activate Akt Signaling in Parkinson’s Disease 
 With mounting evidence to suggest deficiency in Akt signaling as a core component of 
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neurodegeneration in PD, translational approaches to treat PD could involve maintaining the 
phosphorylation status of Akt. Because membrane recruitment is not only a prerequisite, but also 
sufficient for the activation of Akt, controlling localization of Akt to the membrane is an 
effective method of controlling its activation. As such, myristoylated-Akt is commonly used as 
an equivalent to constitutively-active Akt due to its greatly increased phospholipid binding, 
which leads to increased levels of phosphorylated, and therefore active Akt [138, 139, 174]. 
Importantly, interventional approaches to activate Akt signaling are especially attractive due to 
evidence supporting not only its neuroprotective effects, but also potential neurorestorative 
effects in PD models. As mentioned previously, Akt activation has been observed to promote 
neurite outgrowth and axonal branching in a variety of models both in vitro and in vivo [136, 
137, 142, 175]. More contextually relevant to PD, myristoylated-Akt was demonstrated to 
promote neurorestoration of axonal projections from the SNpc to the striatum post-6-OHDA 
insult in mouse models [138]. Similarly, the constitutively-active human Rheb (S16H), a 
downstream effector of Akt signaling, was found to induce regrowth of dopaminergic axons 
post-6-OHDA insult in mouse models [139, 140].  
 The activation of Akt signaling can be achieved by a few different approaches, which 
include pharmacological approaches, delivery of neurotrophic factors, and viral delivery of Akt 
overexpression constructs. Until recently, potential pharmacological activators of the Akt 
signaling pathway were limited to those targeting downstream effectors, such as rapamycin as an 
inhibitor of mTOR [176], or compounds that are reported to indirectly activate Akt, such as 
glucagon like peptide-1 (GLP-1) analogs [177] or rasagiline, a monoamine oxidase-B inhibitor 
that was reported to exhibit neuroprotective effects in preclinical studies but was not proven in 
clinical trials due to failure of dose responsiveness [178, 179]. More recently in 2012, a small 
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molecule activator of Akt (SC79) was identified to specifically bind to the PH domain of Akt, 
inducing a conformational change that allows for phosphorylation of Akt residues, similar to the 
conformational change that occurs when Akt binds to the membrane [180]. Regardless of the 
pharmacological method, however, these approaches have the distinct disadvantage of off-target 
or systemic activation of Akt, which may carry the risk of inducing cancer given the evidence of 
activating Akt mutations described in human cancers [181, 182].  
 Delivery of neurotrophic factors, such as glial cell line-derived neurotrophic factor 
(GDNF), brain-derived neurotrophic factor (BDNF), or neurturin, has long been a therapeutic 
approach of great potential, with strong data supporting their involvement in the pathogenesis of 
PD and potential neuroprotective effects in various PD models both in vitro and in vivo [159, 
160, 183-185]. However, while GDNF showed initial promise in early clinical trials, a 
subsequent placebo-controlled trial showed no significant functional improvement in PD patients 
[186]. The failure of GDNF protein in clinical trials could potentially be due to the metabolism 
of the proteins by endogenous enzymes, patient selection for clinical trials, insufficient dosing, or 
poor diffusion of the neurotrophin from the delivery site. The use of viral vector-mediated 
delivery of neurotrophin genes can circumvent the dose or diffusion issues. Thus, GDNF as well 
as neurturin have entered clinical trials again, utilizing either adeno-associated virus (AAV)-
mediated delivery or improved infusion protocols. However, the latest neurturin trials did not 
yield positive results [187], and GDNF trials are still ongoing [188]. 
 Finally, the use of viral vectors to deliver gene constructs for activation of Akt signaling 
has been validated as a potential therapeutic approach in vivo through AAV1-mediated delivery 
of myristoylated-Akt or constitutively-active Rheb [138, 140]. Furthermore, the safety of gene 
therapy techniques has been validated in clinical trials involving the AAV-mediated delivery of 
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neurturin and human aromatic L-amino acid decarboxylase (hAADC) [187, 189], as well as the 
lentiviral-delivered ProSavin (combination of three genes: AADC, TH, and GTP-cyclohydrase 1) 
[190]. However, the use of a system where Akt is always activated would be disadvantageous as 
a therapy because overactivity of Akt has been clearly linked to diseases such as cancer and has 
the potential for extraneous sprouting of neurites [99, 138, 139]. Thus, there is a need for an 
inducible system in which the activation of Akt can be controlled, ideally under the control of a 
small molecule that is easily administered and has brain penetration.  
 
1.3:  Destabilizing Domain Inducible System 
 Development and Overview of the DD System 
 The ideal therapeutic approach to control Akt activity levels in PD would fulfill four 
general criteria: 1) dose-responsive control of the Akt levels, 2) sufficient and robust activation 
of Akt, 3) reversibility of activation, and 4) minimal off-target effects, through the utilization of a 
well-characterized, activator molecule that is specific to Akt. Although there are many inducible 
systems with the potential for conditional control of Akt expression levels, we chose a novel 
post-translational system with the potential to fulfill these criteria and that is based on control of 
protein stabilization: the Destabilizing Domain (DD) system [191]. Further fulfillment of the 
fourth criteria can be achieved through gene therapy approaches as outlined in the previous 
section, using viral vector-mediated delivery of the DD system to the local brain region of 
interest, the SNpc, in conjunction with a cell type-specific promoter to ensure that the control of 




The DD system allows for the control of protein stability through the presence or absence 
of a cell-permeable compound (Figure 1.2). It was first developed by the Thomas Wandless 
group at Stanford when human FKBP12 mutants were engineered to be rapidly and 
constitutively degraded unless bound to a synthetic ligand, Shield-1 (Shld-1) [192]. Importantly, 
the mutants’ instability was found to be transferred when the mutant FKBP12 proteins were 
fused to other proteins of interest [192]. The mutant FKBP12 proteins were screened to identify 
the most destabilizing mutations with the most efficient rescue upon addition of Shld-1. These 
mutants were further demonstrated to successfully confer Shld-1-dependent stabilization of 
various proteins when genetically fused to either their N- or C-terminus. This held true for a 
variety of proteins differing in size, folding, function, and cellular localization as follows: small 
GTPases Rac1, RhoA, Cdc42, Arf6, Arl7, kinases GSK3β and CDK1, cell cycle regulatory 
proteins securing and p21, transcription factor CREB, and even a transmembrane glycoprotein 
CD8α [192]. Since its discovery, the FKBP12-derived DD inducible system has been validated 
in a variety of organisms including mice [193] and various parasites [194-199], as well as in 
mammalian cell lines [200-204]. Additionally, CRISPR/Cas9 has been used to knock in the 
FKBP12-derived DD domain to the essential gene Treacher Collins-Franceschetti syndrome 1 
 
Figure 1.2: DHFR-derived DD confers inducible stabilityThe DD domain confers 
instability to a fused protein and leads to proteasomal degradation. A stabilizing 
ligand with high specificity to the DD domain stabilizes the entire DD-fusion protein, 








(TCOF1) in human 293T cells as a proof of principle study to demonstrate that the DD inducible 
system can be used to confer small molecule-controlled regulation of an endogenous protein 
[205]. 
  Alternative DD systems have since been developed based on other ligand-protein pairs, 
including E. coli dihydrofolate reductase (DHFR) [191], human estrogen receptor ligand binding 
domain [206], or degrons with light sensitivity for control of protein stability with light  [207]. 
These multiple DD systems permit the orthogonal control of multiple proteins within the same 
cellular system [208]. Of these alternative DD systems, the DHFR-derived version of the DD 
system has additionally been validated in a variety of biological contexts, including parasites 
[209, 210], mammalian cell lines [191, 208, 211, 212], and rodents [191, 211-213]. 
 The mechanism of destabilization and degradation has been further studied in the context 
of both the FKBP12-derived and DHFR-derived DD systems. Initial studies demonstrated that 
inhibition of the proteasome blocks the degradation of both FKBP-derived and DHFR-derived 
DD proteins in the absence of their stabilizing ligands, suggesting that the inducibility of the DD 
system relies on proteasomal degradation [191, 192]. A subsequent investigation of purified 
FKBP12-derived DD fusion proteins in a cell-free system revealed that the DD protein in the 
absence of Shld-1 adopts a misfolded state with the propensity to unfold, whereas the binding of 
Shld-1 stabilizes the DD protein by reversing the unfolded state and folding the protein into a 
more stable structure [214]. Furthermore, when expressed within cells, it was observed that 
unstable DD proteins are rapidly ubiquitinated and tagged for the ubiquitin-proteasome system, 
whereas the presence of Shld-1 was found to prevent the polyubiquitination of DD [214]. 
Interestingly, the data in this study show that the recognition of unstable DD proteins and their 
ubiquitination is rapid, observable within minutes, but that the degradation by the proteasome 
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occurs more slowly, thus suggesting that there will be a pool of ubiquitinated but undegraded 
proteins at steady state [214].  
  
 The DHFR-Derived DD System as a Gene Therapy Approach for PD  
The DHFR-derived DD system controlled by the ligand Trimethoprim (TMP) is of 
particular interest as a potential therapeutic approach due to its use of an inexpensive, well-
characterized, and commonly prescribed antibiotic as the stabilizing ligand [191]. Importantly, 
TMP is known to cross the blood brain barrier [215] and be safe for long-term prophylactic use 
[216-219], thus making this ligand particularly attractive as a therapeutic drug that can exert 
effects in the CNS even when administered orally. As such, the oral administration of TMP for 3 
weeks to control protein stability in the CNS of rodent models has been validated by several 
groups [191, 211-213].  
This DD inducible system shows great potential as a therapeutic approach to control the 
activity levels of Akt in the context of PD. To achieve control over Akt activity levels, the 
DHFR-based DD domain must be genetically fused with a constitutively active form of Akt such 
that any level of stabilization by TMP will lead to direct increase in Akt activity. One such active 
form of Akt is Akt(E40K), a mutant Akt with a glutamate to lysine substitution at E40 [220]. 
This mutant was first engineered in 1998 for use in studies elucidating the activation process of 
Akt and was found to enhance Akt’s membrane binding affinity due to the removal of the 
negatively-charged glutamate from the phospholipid-binding pocket within the PH domain [220, 
221]. With enhanced membrane binding affinity, Akt(E40K) was found to have higher basal 
activity that was sufficient to replicate physiological effects of Akt such as transformation of 
hematopoietic cells and inhibition of apoptosis induced by IL-3 withdrawal [222, 223]. 
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Importantly, a similar form of Akt, Akt(E17K), was found to be neuroprotective against PD 
mimetic toxins in vitro [152]. 
 
1.4:  Significance and Outline 
 Based on the above considerations, we created a DHFR-derived inducible Akt(E40K) 
system. Our rationale was that expression of this protein could be controlled by the ligand TMP 
and would potentially serve as a tool to selectively turn Akt activity on and off in cells as well as 
promote cell survival and neuroprotection in the context of PD. The following chapters report 
our investigation into the utility of DD-Akt(E40K) as a research and clinical tool for control of 
Akt activity and signaling across a variety of biological contexts. Our particular focus is on the 
application of this novel technology as a potential therapeutic approach in Parkinson’s disease. 
 Chapter 2 outlines the experimental methods that were used over the course of this 
research. Chapter 3 describes the in vitro characterization of DD-Akt(E40K) and establishment 
of inducibility across diverse cellular contexts. Chapter 4 explores the biological consequences 
of DD-Akt(E40K) induction in various in vitro cell death paradigms. Chapter 5 expands the in 
vitro studies of DD-Akt(E40K) and investigates its inducible behavior as well as physiological 
effects in mice. Finally, Chapter 6 provides the major conclusions and future directions of this 
research. 
 In summary, this dissertation describes a novel technology that permits the control of 
Akt, a kinase that is crucial to survival signaling, and findings that provide insight into the 





Chapter 2: Materials and Methods 
2.1:  Cell Culture 
 HEK293T/17  
HEK293T/17 cells were grown in DMEM supplemented with 10% FBS and 
penicillin/streptomycin. Cell culture medium was changed every other day. Cells were passaged 
every 1 to 3 days. Cultures were transfected for experiments using Lipofectamine 2000 
(ThermoFisher Scientific) according to manufacturer protocols, 10 µM TMP was added to 
cultures 24 h after transfection, and protein extraction or immunofluorescence staining was 
performed 24 h after TMP treatment. 
 
 PC12 Cells 
PC12 cells were cultured as described previously (Greene and Tischler, 1976) [224]. Cells were 
cultured on plastic cell culture dishes coated with rat tail collagen (Roche). Undifferentiated 
PC12 cells were grown in RPMI 1640 cell culture medium supplemented with 10% heat 
inactivated horse serum (Sigma), 5% FBS, and penicillin/streptomycin. For neuronal 
differentiation, cells were grown in RPMI 1640 cell culture medium supplemented with 1% 
horse serum, penicillin/streptomycin, and 50 ng/ml final concentration of human recombinant 
NGF (kind gift of Genentech, Gemini Bio-Products #300-174P). Cell culture medium was 
changed every other day. Lentivirus was added to the cultures at an approximate MOI of 5-10 on 
day 1-2 in vitro of undifferentiated cultures and 4-5 in vitro of differentiated cultures, 10 µM 
TMP was added to cultures 4-5 days after infection, and protein extraction was performed 24 h 




 Primary Rat Cortical Neurons 
Primary cortical cultures were prepared as previously described [225]. Briefly, cortices were 
isolated from E18 rat embryos, dissociated, and plated on poly-D-lysine (Sigma) coated plates at 
a density of 3 x 105 cells/well. Cultures were maintained in Neurobasal medium (ThermoFisher 
Scientific) supplemented with 2% B-27 (ThermoFisher Scientific) and 0.5 mM glutamine 
(ThermoFisher Scientific). Half of the medium was changed every 3 days after plating. 
Lentivirus was added to the cultures at an approximate MOI of 5-10 on day 5-7 in vitro and 
protein extraction was performed 4-7 days after infection. 
 
 Primary Ventral Midbrain Dopaminergic Neurons 
Ventral midbrain dopaminergic neurons from P0-P3 rats were dissected, dissociated, and plated 
on a confluent glial monolayer following the protocol kindly provided by Dr. David Sulzer 
(Columbia University) and as described previously (Rayport et al., 1992) [226]. Briefly, 1 mm3 
blocks were dissected from the substantia nigra of a coronal midbrain slice, according to 
anatomical landmarks, and enzymatically dissociated in a papain solution for 20-30 minutes. 
Digested tissue blocks were rinsed and triturated 10 times with large-bore tech tips, 10 times 
with medium-bore tech tips, and 10 times with small-bore tech tips. Cells were centrifuged, 
resuspended in SF1C medium, and plated at a density of 80,000 cells per dish on top of a glial 
monolayer. Cultures were treated with GDNF (10 ng/ml) and processed as needed for 
experiments. Lentivirus was added to the cultures at an approximate MOI of 10 on day 6-7 in 
vitro, 10 µM TMP was added to cultures 6-10 days after infection, and processed for 




2.2:  PI3K Inhibitor Experiments 
HEK293 cells transfected with DD-Akt(E40K) or pWPI empty vector plasmids were pretreated 
with 10 µM TMP for 24 h and treated with 50 µM LY294002 (Cell Signaling Technology 
#9901). Protein extraction was performed at 24 h after LY294002 addition. 
 
2.3:  Cell Death Paradigms  
 Serum Deprivation 
For serum deprivation of undifferentiated PC12 cells, cells were detached from wells with 
serum-free RPMI 1640 and pelleted at 1500 rpm for 5 min. Pellets were washed in serum-free 
RPMI 1640 and spun again at 1500 rpm for 5 min. Cells were resuspended in serum-free RPMI 
1640 or RPMI 1640 medium supplemented with 10% heat inactivated horse serum (Sigma) and 
5% FBS, corresponding to experimental conditions, and plated at a density of 5 x 105 cells/ml. 
Cells were analyzed for survival 24 h after serum deprivation.  
 
 PD Toxins 
For neuronal PC12 cells, 10 mM stock solutions of 6-hydroxydopamine (Tocris) or 1-methyl-4-
phenylpyridinium (MPP+) (Sigma) diluted in water were freshly prepared just before each 
experiment. 6-OHDA was used at final concentrations ranging from 100 to 150 μM, and MPP+ 
was used at a final concentration of 0.25 mM, for 16-24 h.  
 
2.4:  Quantification of Cell Survival In Vitro 
For PC12 cells infected with lentiviral particles (typically achieving a 50% transduction rate in 
undifferentiated PC12 cells and 75% transduction rate in differentiated PC12 cells) and treated 
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with PD toxins or deprived of serum, cell survival was assessed on the total cell population level 
by incubating the cell cultures with a detergent solution that lyses the plasma membrane and 
leaves the nuclei intact (10x counting lysis buffer: 5 g of cetyldimethyl-ethanolammonium 
bromide, 0.165 g of NaCl, 2.8 ml of glacial acetic acid, 50 ml of 10% Triton-X, 2 ml of 1 M 
MgCl2, 10 ml of 10 × PBS, 35.2 ml of H2O); 150 μl of 1x counting lysis buffer was added per 
cm2 of culture dish area, and the suspended nuclei were counted in a hemacytometer. 
 
2.5:  Cloning 
  DD-Akt(E40K) 
The DHFR-derived DD-YFP gene insert in a pBMN vector was obtained from Addgene 
(Plasmid #29325). The HA-tagged mouse Akt1(E40K) plasmid was provided by our 
collaborator, Dr. Thomas Franke. The HA-Akt1(E40K) gene insert (from here on called 
Akt(E40K)) was amplified using PCR and primers as follows: Fwd 5'-
gcgcatgcTACCCATACGATGTTCCAGATT-3' and Rev 5'-
atccgcggTCAGGCTGTGCCACTGG-3'. The amplified Akt(E40K) gene was inserted 3’ of the 
DD domain, replacing YFP, in a pBMN vector using restriction sites Sph1 and SacII to create 
pBMN-DD-Akt(E40K). The entire DD-Akt(E40K) gene was then inserted using restriction sites 
BamHI and SacII and blunt-end ligation into the overexpression vector pWPI (Addgene, Plasmid 
#12254), a bicistronic lentiviral vector allowing the simultaneous expression of the transgene and 
EGFP under the control of the EF1-α promoter.  
 
 DD-Akt(WT) 
Akt(WT) was amplified from mouse cDNA using primers as follows: Fwd 5'-
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tctagcgcatgcATGAACGACGTAGCCATTGTGAA-3' and Rev 5'-
cattatccgcggTCAGGCTGTGCCACTGGCTGA-3'. The amplicon was inserted 3’ of the DD 
domain, replacing YFP, in a pBMN vector using restriction sites Sph1 and SacII to create 
pBMN-DD-Akt(WT). 
 
 Double DD-Akt(E40K)  
All double DD-domain constructs were generated using the In-Fusion Cloning kit from 
Clontech. Primers were designed using the online tool provided by Clontech specifically for this 
cloning technique. Glycine linkers (Gly-Gly-Gly-Gly-Ser) were generated using GenScript 
Codon Usage Frequency Table Tool (http://www.genscript.com/tools/codon-frequency-table) to 
determine most common codons within the human and rat species. Linkers were inserted in 
between the two DD domains and in between the DD domains and Akt gene as indicated in 
Figure 3.13. A Kozak sequence (5’-TCCGCCACC-3’) was inserted 5’ of the ATG start site. The 
complete insert was concurrently cloned into a pWPI expression vector.  
 
 
2.6:  Biochemistry 
 Western Immunoblotting 
Cells and brain tissue were homogenized in 1x cell lysis buffer (Cell Signaling Technology, 
#9803) with LDS-sample buffer (Invitrogen) supplemented with 50mM dithiothreitol and 
complete mini protease inhibitor mixture (Roche, #11836170001), or in 1x sample buffer (5x 
sample buffer: 250 mM Tris-HCl pH 6.8, 10% SDS, 0.5% bromophenol blue, 50% glycerol, 5% 
2-hydroxy-1-ethanethiol). Lysates were boiled at 100°C for 10-20 min prior to running. A total 
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of 20 μg of proteins was loaded per well of 10% or 4-12% Bis-Tris polyacrylamide gels 
(Invitrogen) and separated by electrophoresis for 1.5 h at 100 V. Proteins were then transferred 
onto a nitrocellulose membrane (Bio-Rad) for 1 h 30 min at 40 V. Membranes were blocked with 
5% powdered milk in TBS containing 0.1% of Tween 20 (TBST) and incubated overnight at 4°C 
with primary antibodies. The following primary antibodies were used for Western blotting: 
rabbit anti-phospho-Akt (Thr308) (Cell Signaling Technology #13038, #2965), mouse anti-
phospho-Akt (Thr308) (Cell Signaling Technology #5106), rabbit anti-phospho-Akt (Ser473) 
(Cell Signaling Technology #4060), rabbit anti-pan-Akt (Cell Signaling Technology #4685), 
rabbit anti-phospho-FoxO4 (Cell Signaling Technology #9471), rabbit anti-total FoxO4 (Cell 
Signaling Technology #2499), mouse anti-actin (Sigma #A3853), GAPDH (Abcam), and rabbit 
anti-Erk1/2 (Santa Cruz Biotechnology, #sc-93). Membranes were washed 3 times with TBST 
and incubated with HRP-conjugated secondary antibodies or IRDye secondary antibodies (Li-
Cor, goat anti mouse #680LT, goat anti rabbit #800CW). After 3 final washes with TBST, blots 
were incubated with ECL reagents (GE Healthcare), and chemiluminescent signals were detected 
by exposure to autoradiography film, or blots were imaged using a Li-Cor Odyssey CLX 
imaging system. Films were scanned using a desktop scanner, and band intensities were 
determined using ImageJ, or Odyssey images were analyzed using Image Studio Lite Ver 4.0. 
 
 Immunofluorescence 
Cells were fixed for 12–15 min in 4% PFA and washed 3 times with 1x PBS. Cells were blocked 
with Superblock (Thermo Scientific) supplemented with 0.3% Triton-X for 1 h at room 
temperature and incubated overnight at 4°C with primary antibodies. The following primary 
antibodies were used for immunofluorescence: mouse anti-tyrosine hydroxylase (Millipore, 
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#MAB318), rabbit anti-tyrosine hydroxylase (Millipore, #AB152), rabbit anti-GFP (Invitrogen, 
#A11122), chicken anti-GFP (Invitrogen, #A10262), mouse anti-HA (Cell Signaling 
Technology, #2367), and rabbit anti-phospho-Akt (Thr308) (Cell Signaling Technology, 
#13038). Cells were washed 3 times with PBS and incubated with fluorescent secondary 
antibodies for 1-2 h at room temperature: AlexaFluor-568 anti-mouse, or anti-rabbit, AlexaFluor-
488 anti-chicken, anti-mouse, or anti-rabbit, and AlexaFluor-350 anti-mouse or anti-rabbit 
(Invitrogen). For HEK293 cells grown in multiwell dishes, Hoechst 33328 was added to the first 
PBS wash, cells were washed 2 additional times in PBS, and cultures were observed with an 
inverted fluorescence microscope. For ventral midbrain dopaminergic neurons grown on glass 
coverslips, after 3 final washes with PBS, coverslips were mounted on slides with Vectashield 
mounting medium containing DAPI for nuclear staining (Vector Laboratories). Images were 
acquired using an Olympus inverted or upright fluorescent microscope equipped with a digital 
camera and Cellsens software. 
 
2.7:  Rodent Husbandry and Handling 
All rodent procedures were approved by the Columbia University Institutional Animal 
Care and Use Committee. 
 
2.8:  Preparation and Injection of Viral Vectors 
 Lentivirus 
All viral plasmids were obtained from Addgene. The transfer plasmid for overexpression was 
pWPI, which encodes transgene-IRES-GFP under the control of the EF1-alpha promoter. 
Viruses were prepared in HEK293T cells using second-generation packaging plasmids pMD2G 
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and psPAX2 (obtained through Addgene) through calcium phosphate transfection. Lentiviral 
supernatants were collected twice (48 h and 72 h after transfection) and concentrated using 
Lenti-X concentrator (Clontech, #631231) according to manufacturer protocols, resuspended in 
PBS, and stored at -80°C.  
 
For transduction of neuronal cultures, 5-10 MOI were added directly in the medium of neuronal 
PC12 cells, primary cortical neurons, or ventral midbrain dopaminergic neurons. Transduced 
neurons were analyzed by western blot or immunofluorescence after 5-7 days.  
 
 Adeno-Associated Virus 
All vectors used for these studies were AAV1 serotype. For AAV vector generation, the DD-
HA-Akt(E40K) gene was modified to incorporate a Flag-encoding sequence (5’-
GACTACAAAGACGATGACGACAAA-3’) (denoted as DD-Akt(E40K)-Flag in Chapter 5) 
and inserted into an AAV packaging construct that utilizes the chicken β-actin promoter and 
contains a 3′ WPRE (pBL) as previously described (Ries et al, 2006) [138]. Similarly, an 
Akt(E40K) insert with no DD domain was modified to incorporate a Flag-encoding sequence 
and inserted into an AAV packaging construct (pBL). All nucleotide sequences in the AAV 
packaging constructs were confirmed before AAV production. AAVs were produced by the 
University of North Carolina Vector Core. The viral titer of AAV-DD-Akt(E40K)-Flag was 2.3 
x 1011 viral molecules/ml and those of AAV-Akt(E40K) was 4.9 x 1012 viral molecules/ml.  
 
For AAV injections, adult (8 week) male C57BL/6 mice were obtained from Charles River 
Laboratories, Wilmington, MA. Mice were anesthetized with ketamine/xylazine solution and 
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placed in a stereotaxic frame (Kopf Instruments, Tujunga, CA) with a mouse adapter. For 
intranigral injections, the tip of a 5.0 µl syringe needle (26S) was inserted to stereotaxic 
coordinates AP: −0.35 cm; ML: +0.11 cm; DV: −0.37 cm, relative to bregma. For intrastriatal 
injections, the tip of a 5.0 µl syringe needle (26S) was inserted to stereotaxic coordinates AP: 
+0.09 cm; ML: +0.22 cm; DV: -0.25 cm relative to bregma. Viral vector suspension in a volume 
of 2.0 µl was injected at 0.1 µl/minute over 20 minutes. 
 
2.9:  Oral Trimethoprim (TMP) Administration 
Six out of 13 mice injected with intranigral DD-HA-Akt(E40K)-Flag injections and 8 out of 13 
mice with intrastriatal DD-HA-Akt(E40K)-Flag injections were given freshly 1.31 mg/ml TMP-
lactate, which is an equivalent of 1 mg/ml TMP, in their drinking water. TMP solutions were 
covered with aluminum foil to protect from light exposure and changed every 2-4 days for 3 
weeks. 
 
2.10:  Immunohistochemical Processing 
 Tyrosine Hydroxylase (TH) Immunostaining 
For TH immunostaining, mice were perfused with 0.9% NaCl for 5 min followed by 4% 
paraformaldehyde in 0.1 M phosphate buffer for 10 min. The brain was postfixed for 1 week, 
cryoprotected in 20% sucrose overnight, and then rapidly frozen by immersion in isopentane on 
dry ice. A complete set of serial sections was then cut through the SN at 30 µm. Beginning with 
a random section between 1 and 4, every fourth section was processed free-floating. Primary 
antibodies used were rabbit anti-TH (Calbiochem #657012) at 1:750. Sections were treated with 
biotinylated protein A and avidin-biotinylated horseradish peroxidase complexes (ABC; Vector 
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Labs, Burlingame, CA). After immunoperoxidase staining, sections were mounted, dehydrated, 
and analyzed for neuronal cell size quantification. 
 
 Flag Immunostaining 
For immunostaining of the FLAG epitope, perfused mouse brains were postfixed for 24 h, 
cryoprotected in 20% sucrose overnight, and then rapidly frozen by immersion in isopentane on 
dry ice. A complete set of serial sections was then cut through the SN or striatum at 30 µm. 
Nigral sections from a complete set were chosen as for TH immunostaining (described above). 
For striatal sections, beginning with a random section between 1 and 6, every sixth section was 
chosen for immunostaining. Chosen sections were treated with Mouse-on-Mouse Blocking 
Reagent (Vector Labs) and processed free-floating with a mouse monoclonal anti-Flag antibody 
(Sigma, St Louis, MO) at 1:1000. Sections were incubated with biotinylated anti-mouse IgG 
(Vector Labs), followed by ABC (Vector Labs). After immunoperoxidase staining, sections were 
mounted, dehydrated, and analyzed for neuronal counts using stereological analysis or thionin-
counterstained for neuronal cell size analysis. 
 
2.11:  Quantitative Analysis of Neurons In Vivo 
 Stereological Analysis  
To determine the number of Flag-positive neurons in the SN, the entire SN was identified as the 
region of interest within the StereoInvestigator program (MicroBrightField, Williston, VT). A 
fractionator probe was established for each section. The number of Flag-positive neurons in each 
counting frame was determined by focusing down through the section, using x100 objective 
under oil, as required by the optical dissector method. Our criterion for counting an individual 
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TH-positive neuron was the presence of its nucleus either within the counting frame, or touching 
the right or top frame lines (green), but not touching the left or bottom lines (red). The total 
number of Flag-positive neurons for each brain was then determined by the StereoInvestigator 
program. 
 
 Neuronal Size Analysis 
To determine the size of injected SN neurons, the StereoInvestigator program was used. For each 
brain hemisphere, five representative sections (one caudal, two middle, two rostral) were chosen, 
and five neurons from each section were selected at random sites within the SN to provide a total 
of 25 neurons per brain per condition (uninjected vs. injected). The area of each neuron cell body 
was determined under x100 objective under oil. The contralateral, uninjected hemisphere for 
each mouse brain was used for control neuron sizes. 
 
2.12:  Statistical Analysis 
All statistical analyses were performed with GraphPad Prism software. Simple comparisons of 
two experimental groups were performed using t-tests. Multiple comparisons of more than two 
experimental groups were performed using two-way ANOVA and Tukey’s multiple comparisons 
test. The threshold of significance was set at α = 0.05 for all experiments. 
 
2.13:  Materials 
 Antibodies 
Target Species Dilution Company Catalog # 




pAkt308 Mouse 1:1000 (western blot) Cell Signaling Technology 5106 
pAkt308 Rabbit 1:1000 (western blot) 
1:1600 (IF) 
Cell Signaling Technology 13038 
pAkt308 Rabbit 1:1000 (western blot) Cell Signaling Technology 2965 
pAkt473 Rabbit 1:1000 (western blot) Cell Signaling Technology 4060 
Total Akt Rabbit 1:1000 (western blot) Cell Signaling Technology 4685 
pFoxO4 Rabbit 1:1000 (western blot) Cell Signaling Technology 9471 
Total FoxO4 Rabbit 1:400 (western blot) Cell Signaling Technology 2499 
GFP Rabbit 1:1000 (IF) Invitrogen A11122 
GFP Chicken 1:1000 (IF) Invitrogen A10262 
Actin Mouse 1:3000 (western blot) Sigma A3853 
GAPDH Mouse 1:5000 (western blot) Abcam ab9484 
ERK1/2 Rabbit 1:5000 (western blot) Santa Cruz SC-93 
TH Mouse 1:1000 (IF) Millipore MAB318 
TH Rabbit 1:1000 (IF) Millipore AB152 
TH Rabbit 1:750 (IHC) Calbiochem 657012 
Flag Mouse 1:1000 (IHC) Sigma F3165 
 
 Other Reagents 
Name Description Company Catalog # 





Trimethoprim DD stabilizing ligand Sigma 92131 
Trimethoprim-lactate DD stabilizing ligand ChemImpex International 03552 
Vectastain ABC HRB kit Peroxidase staining Vector Laboratories PK-400 
Mouse on Mouse kit Immunohistochemistry 
for mouse antibodies 





Chapter 3: Creation and Validation of DD-Akt(E40K) 
3.1:  Introduction 
 The destabilizing domain (DD) system was developed as a means for inducible protein 
control. It was first created by Thomas Wandless in which human FKBP12 protein was 
engineered to confer instability to other proteins when fused to the DD domain, and this 
instability was reversible by the addition of a synthetic FKBP12 ligand, Shield-1 (Shld1) [192]. 
The engineered destabilizing domain has the propensity to become misfolded or partially 
unfolded and rapidly promotes the ubiquitination of the protein, marking it for proteasomal 
degradation [214]. When the Shld1 is added, it binds the FKBP12-derived DD domain within a 
cavity formed by an F36V mutation, inducing the stable and folded conformation of the DD 
domain and preventing its degradation [214]. 
Through further engineering of the DD domain, the Wandless group discovered that 
Shld1-dependent stabilization can be conferred to a variety of proteins of different sizes, folding, 
function, and cellular localization [192]. Furthermore, this DD system was demonstrated to 
confer inducible regulation of secreted proteins in a dose-dependent manner in mice [193].  
The Wandless group subsequently engineered a second destabilizing domain based on E. 
coli dihydrofolate reductase (DHFR), which can be stabilized by the antibiotic Trimethoprim 
(TMP) [191]. Similar to the FKBP12-derived DD system, DHFR-derived DD can confer 
instability if fused to a protein of interest, leading to its degradation via the proteasome [191]. 
The addition of TMP will stabilize the DD-fusion protein, allowing it to then accumulate within 
the cell. This version of the DD system was demonstrated to be effective at control of protein 
stability when placed at the N-terminus or C-terminus, thus providing flexibility of DD domain 
placement within the protein of interest [191]. Furthermore, the DHFR-derived DD system has 
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the significant advantage of utilizing TMP, an FDA-approved antibiotic commonly used for 
treatment of urinary tract infections, as the stabilizing ligand. TMP has been demonstrated to be 
safe for long-term prophylactic use and can cross the blood brain barrier effectively [215-219]. 
Importantly, the DHFR-derived DD system has been demonstrated by several groups to be 
inducible in the rodent striatum with oral administration of TMP [191, 211-213]. These 
characteristics of the DHFR-derived DD system suggest that it can be utilized as a therapeutic 
strategy in Parkinson’s disease to regulate protein levels within the CNS with systemic 
administration of TMP. 
 To fulfill our objective to create an inducibly active Akt system, we have chosen to 
genetically fuse DHFR-derived DD to the N-terminus of our protein of interest, the constitutively 
active Akt(E40K), which was provided by our collaborator, Dr. Thomas Franke. Specifically, 
this construct was chosen for its constitutively high activity, which would allow for accumulation 
of active Akt when fused to the DD domain and treated with the stabilizing ligand, TMP (Figure 
3.1). High constitutive activity of Akt is especially critical for a therapeutic approach in PD, as 
reports of disrupted PI3K/Akt signaling in the disease imply that simply increasing wild type Akt 
levels may not sufficiently increase Akt-mediated survival signaling if upstream signaling 




The Akt(E40K) construct used here consists of the mouse Akt1 isoform with a glutamate 
to lysine substitution at E40, which is predicted to lie within the phospholipid binding pocket of 
the PH domain [221]. This mutant was first engineered for use in studies elucidating the 
activation process of Akt [220]. The substitution mutation at E40 was found to enhance the 
binding affinity of Akt to phospholipids at the plasma membrane due to the removal of the 
negatively charged glutamic acid within the phospholipid binding pocket. The enhanced 
membrane translocation led to higher basal activity of Akt(E40K), which was sufficient to 
replicate biological effects of Akt activity, including transformation of hematopoietic cells and 
inhibition of apoptosis induced by IL-3 withdrawal [222, 223]. Overexpression of Akt(E40K) 
has been shown to protect against growth factor-induced apoptosis in vitro [227] as well as 
increase angiogenesis and reduce apoptosis in vivo in a pressure overload-induced heart failure 
mouse model [228]. Another mutant form of Akt with a similar mutation in the PH domain, 
Akt(E17K), has been demonstrated in vitro to protect against PD mimetic toxins, further 
supporting the hypothesis that Akt(E40K) can potentially exhibit neuroprotective effects [152].  
There also exist phosphomimetic mutants of Akt wherein the canonical phosphorylation 
sites Thr308 and Ser473 are substituted with an aspartate residue to mimic a phosphorylated 
 
Figure 3.1: DD-Akt(E40K) is inducibly stabilized by TMP 
The DD-Akt(E40K) protein is unstable and degraded through the proteasome. 
Trimethoprim (TMP) stabilizes the fusion protein through binding of the DD domain, 








residue [229]. However, these mutants have been found to have low oncogenicity and signaling 
activity compared to myristoylated Akt or Akt(E40K), suggesting that phosphomimetic Akt 
mutants do not recapitulate all biological effects of active Akt, [229, 230].  
High constitutive activity of Akt may also be achieved through the addition of a 
myristoylation sequence to the N-terminus of the kinase [231]. However, we chose not to use 
this form of Akt for two different reasons: better fine-tune control of Akt activity and simpler 
construct generation. To the first point, myristoylated Akt (myr-Akt) has been suggested to have 
higher activity levels than that of PH domain mutants, as is implied by much larger increases in 
heart size with overexpression of myr-Akt compared to Akt(E40K) in rats [232, 233]. Thus, 
fusion of the DD domain to a constitutively active Akt with lower activity levels, such as 
Akt(E40K), would potentially allow for better tunability of Akt activity and a wider dose-
responsive window. To the second point, generating a myr-DD-Akt construct would require the 
combination of three elements (a myristoylation sequence, DD domain, and Akt kinase) 
compared to the two in a DD-Akt(E40K) construct, which would require a more complicated 
cloning strategy for unclear added benefit. 
Although the DHFR-derived DD system provides the flexibility of being placed at the C- 
or N-terminus of the protein of interest, the C-terminus of Akt contains a highly conserved 
hydrophobic region that has been shown to be critical for stimulating kinase activity by 
stabilizing the active state of Akt and serving as a docking site to mediate substrate interactions 
[110, 115, 234]. Thus, to avoid the possibility of a C-terminal DD domain hindering Akt 
function, we chose to place the N-terminal DHFR-derived DD domain (from Addgene plasmid 
#29325) at the 5’ end of the Akt(E40K) expression construct, which also includes an HA tag for 
ease of identification in biochemistry experiments (Figure 3.2). The fusion gene was 
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subsequently cloned into a pWPI lentiviral overexpression plasmid and confirmed through 
Sanger sequencing. The resulting DD-Akt(E40K) fusion protein would be expected to be tunable 
through TMP treatment and have rapid and reversible induction. Specifically, with the addition 
of TMP to the extracellular milieu, TMP would bind to the DHFR-DD domain, stabilizing the 
fusion protein and allowing DD-Akt(E40K) to become activated and accumulate within the cell. 
 In this chapter, we introduce the in vitro characterization of the regulation of DD-
Akt(E40K). An inducibly active Akt that utilizes a system based on protein stabilization and 
under the control of a widely-used antibiotic has not previously been demonstrated. With the 
importance of Akt signaling in normal cell function and in a wide variety of degenerative 
diseases as well as cancer, a robust inducible Akt system would have potentially wide 
implications as a research tool to further elucidate Akt signaling in disease states as well as 







3.2:  Results 
 Validation of DD-Akt(E40K) Inducibility 
The DD inducible system has not previously been applied to create a tunable form of the 
kinase Akt. To first validate the inducibility of the DHFR-derived DD construct that we obtained 
through Addgene (Plasmid #29325), the expression construct was transiently transfected into 
 
 
Figure 3.2: DD-Akt(E40K) construct and protein 
(A) The HA-tagged DD-Akt(E40K) construct was cloned into a pWPI vector.  
(B) The DD-Akt(E40K) fusion protein contains a DD domain for inducible stability, an E40K 











HEK293T cells in the form of the fusion gene, DHFR(DD)-YFP. TMP at the dose of 10 µM was 
added to the cell culture medium at 24 hours post-transfection in order to allow for protein 
expression of transfected constructs to reach steady state. A 10 µM dose of TMP was chosen 
based on previous in vitro studies of the DHFR-DD system demonstrating efficient control of 
DD-YFP with 10 µM TMP [191]. Cells were treated for 24 hours to allow for stabilization and 
accumulation of the DD-YFP fusion protein, after which the cells were imaged with an 
epifluorescence microscope to assess levels of YFP across conditions (Figure 3.3). The results 
demonstrate clear induction in levels of YFP fluorescence with TMP treatment in cells that were 
successfully transfected, while there was no YFP fluorescence observed in untreated cells. This 
thus confirmed that the DHFR-derived DD system can control the stabilization of YFP as 





Figure 3.3: DD-YFP is inducible in HEK293 cells 
HEK293T cells were transfected with a bicistronic IRES expression vector 
containing a DHFR(DD)-YFP fusion gene and an hcRed gene under the same 
promoter (Plasmid #29325, Addgene). Cells were treated with 10 µM TMP for 
24 hours and imaged with an epifluorescence microscope. Red fluorescence 
indicates cells expressing the vector and green fluorescence indicates levels of 











To validate the inducibility of the DD-Akt(E40K) fusion protein, the expression vector 
was transiently transfected into HEK293T cells. The expression vector contains an IRES to allow 
for bicistronic expression of both DD-Akt(E40K) as well as GFP as a readout for successful 
transfection (Figure 3.2A). To allow for protein expression of transfected constructs to reach 
steady state, 10 µM TMP was added to the cell culture medium 24 hours after transfection to 
start stabilizing the fusion protein. After 24 hours of TMP treatment, the cells were then 
processed for immunofluorescence staining of GFP to identify transfected cells and HA to 
identify expression levels of the HA-tagged DD-Akt(E40K) protein. We observed that treatment 
with TMP led to increased levels of HA staining within the cultures that were transfected with 
pWPI-DD-Akt(E40K), demonstrating that the TMP treatment indeed leads to stabilization and 
accumulation of DD-Akt(E40K) in vitro in HEK293T cells as was anticipated (Figure 3.4). 
There was a slight level of HA staining in cultures transfected with DD-Akt(E40K) but untreated 
with TMP compared to cultures transfected with an empty vector (pWPI), indicating that there is 




As discussed above, Akt(E40K) has enhanced membrane binding affinity, which 
promotes its activation. To determine whether treatment with TMP would also lead to enhanced 
levels of phosphorylated Akt due to induction of total DD-Akt(E40K) protein levels, HEK293T 
cells were transfected with the DD-Akt(E40K) construct, treated with 10 µM TMP for 24 hours, 
and processed for immunofluorescence staining of pAkt308 to identify the levels of 
phosphorylated, and therefore active, Akt present within the cells (Figure 3.5).  We observed 
robust induction of active Akt within transfected cells with TMP treatment, thus paralleling the 
increased expression of stabilized DD-Akt(E40K) (Figure 3.4). There was a low background 
level of active Akt detected in certain cells within cultures that were not treated with the 
stabilizing ligand, which may reflect a combination of background staining, endogenous 































Akt(E40K) is inducible 
in HEK293 cells 
HEK293T cells were 
transfected with a 
bicistronic IRES 
expression vector (pWPI) 
containing the DD-
Akt(E40K) fusion gene 
and an eGFP gene. Cells 
were treated with 10 µM 
TMP for 24 hours and 
then fixed for 
immunofluorescence 
staining. GFP staining 
indicates cells expressing 
the vector and HA 
indicates levels of DD-
Akt(E40K) protein. Scale 




The induction in activated Akt was also apparent when cells were processed for western 
immunoblotting (Figure 3.6). With the addition of the DHFR-derived DD domain, DD-
Akt(E40K) can be easily distinguished from endogenous Akt due its higher molecular weight 
and therefore lower electrophoretic mobility. The average fold induction levels across 8-9 
experiments was found to be 2.6-fold ± 0.2 for total Akt levels (p < 0.001 vs. -TMP), 2.7-fold ± 
0.4 for phosphorylated Akt at the S473 site (p < 0.01 vs. -TMP), and 4.9-fold ± 1.0 for 
phosphorylated Akt at the T308 site (p < 0.01 vs. -TMP). It should be noted that fold-induction 
was variable across experiments primarily due to variability in the detectable background levels 
of DD-Akt(E40K) when not treated with TMP. This variability was particularly apparent for the 
pAkt308 site where fold inductions ranged from 1.6-fold to 10.8-fold across independent 
experiments. Across independent experiments, the induction of pAkt473 ranged from 1.7-fold to 
4.5-fold and total Akt ranged from 1.9-fold to 3.7-fold. 
 
 
Figure 3.5: TMP treatment induces active DD-Akt(E40K) in HEK293 cells 
HEK293T cells were transfected with a bicistronic IRES expression vector 
(pWPI) containing the DD-Akt(E40K) fusion gene and an eGFP gene. Cells 
were treated with 10 µM TMP for 24 hours and then fixed for 
immunofluorescence staining. GFP staining indicates cells expressing the 














The inducibility of DD-Akt(E40K) was further tested to assess its utility and consistent 
inducibility across different cell types, such as neuronal cell types, with higher relevance to 
potential applications in PD. Because neuronal cell types tend to be difficult to transfect using 
traditional methods, DD-Akt(E40K) was packaged into a lentiviral vector for transduction and 
overexpression.  
The first neuronal cell type in which DD-Akt(E40K) inducibility was test was neuronal 
PC12 cells. PC12 cells were differentiated as described in Chapter 2 for 4-5 days and 
subsequently infected with either an empty lentiviral vector or a DD-Akt(E40K)-containing 
 
 
Figure 3.6: DD-Akt(E40K) is consistently inducible in HEK293 cells 
HEK293T cells were transfected with either an empty expression vector (pWPI) or an 
expression vector containing the DD-Akt(E40K) fusion gene. Cells were treated with 10 µM 
TMP for 24 hours and then lysed for western blotting. (A) A representative blot of the 
expression levels of phosphorylated and total DD-Akt(E40K). “DD-Akt” indicates DD-
Akt(E40K) protein bands and “Endo-Akt” indicates endogenous Akt protein. (B) Average 
fold induction with TMP treatment. N = 8-9 experiments each, with duplicate or triplicate 
wells per condition. Graph shows means with SEM. **p < 0.01, ***p < 0.001, paired t-test 
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lentiviral vector. The cells were treated with 10 µM TMP for 24 hours at 3-4 days post-
transduction to allow for full expression of DD-Akt(E40K). Cultures were subsequently 
processed and analyzed by immunoblotting to determine levels of DD-Akt(E40K) induction with 
TMP treatment (Figure 3.7). Mean levels of induction in neuronal PC12 cells across 4-6 
independent experiments were comparable to those found in HEK293 cells with 2.6-fold ± 0.3 
induction for pAkt308 (p < 0.05 vs. -TMP), 3.6-fold ± 0.7 induction for pAkt473 (p < 0.05 vs. -
TMP), and 11.9-fold ± 2.7-fold induction for total Akt (p < 0.05 vs. -TMP). Additionally, to 
understand how phosphorylated DD-Akt(E40K) induction relates to endogenous pAkt signaling, 
the levels of phosphorylated DD-Akt(E40K) were quantified and compared to endogenous pAkt 
levels (Figure 3.8). When the phosphorylated DD-Akt(E40K) levels with TMP treatment were 
calculated as a percentage of endogenous pAkt, phosphorylated DD-Akt(E40K) at the pAkt308 
site was found to reach 131.3% ± 27.6% and the pAkt473 site was found to reach 109.0% ± 
22.9%. Although transduction efficiency was not assessed in all experiments, efficiency was 
approximately 75% for these experimental conditions, as measured by the proportion of GFP-





DD-Akt(E40K) was additionally tested in primary neuronal cultures (Figure 3.9). The 
induction levels were measured in primary rat cortical cultures with similar methods as in 
neuronal PC12 cells and as described in Chapter 2. The mean induction levels in one 
independent experiment with duplicate cultures were measured to be 2.0-fold ± 0.1 (p < 0.05 vs. 
-TMP) at the phosphorylated serine site, and 3.7-fold ± 0.07 (p < 0.01 vs. -TMP) of total Akt, 
 
Figure 3.7: DD-Akt(E40K) is inducible in neuronal PC12 cells 
Neuronal PC12 cells were transduced with a lentiviral vector containing either an empty 
expression vector (pWPI) or an expression vector containing the DD-Akt(E40K) fusion 
gene. 4-5 days post-transduction, cells were treated with 10 µM TMP for 24 hours and then 
lysed for western blotting. (A) A representative blot of the expression levels of 
phosphorylated DD-Akt(E40K) (indicated by “DD-Akt”) and endogenous Akt (indicated by 
“Endo-Akt”). (B) Average fold induction with TMP treatment. N = 4-6 experiments, with 
duplicate or triplicate wells per condition. Graph shows means with SEM. *p ≤ 0.05, paired 



























































1 7 5 Figure 3.8: DD-Akt(E40K) reaches control endogenous 
pAkt levels in neuronal PC12 cells 
Neuronal PC12 cells were transduced with DD-
Akt(E40K) lentiviral overexpression constructs and 
treated with 10 µM TMP for 24 hours and then lysed for 
western immunoblotting. The percentage of 
phosphorylated DD-Akt(E40K) to endogenous pAkt 
levels was quantified and calculated as a percent ratio. 
N=4-6 independent experiments. Graphs are means with 
SEM. Transduction efficiency estimated to be 75%. 
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with a transduction efficiency of 50.4% (Figure 3.9). If transduction efficiency is considered, the 
actual fold induction on a per cell basis may be higher, up to a maximum of double what is 
quantified in this experiment (4-fold increase at S473 and 6.4-fold increase of total Akt). 
However, it is probable that increased transduction rates would also increase the detected basal 
levels proportionally, which may lead to minimal changes in fold-induction. Overall, the 
induction levels in primary cortical neurons were found to be comparable to induction levels 
observed in HEK293 and neuronal PC12 cell cultures, thus demonstrating successful TMP-
mediated DD-Akt(E40K) inducibility in these cultures. 
 
Finally, the DD-Akt(E40K) system was tested in primary dopaminergic neuron cultures 
to determine its utility as an inducible system in a cell type that is most relevant to Parkinson’s 
disease. Ventral midbrain dopaminergic neurons were isolated from P0-P3 rats and plated on a 
confluent glial monolayer as per the protocol utilized in Dr. David Sulzer’s laboratory [226]. Due 
 
 
Figure 3.9: DD-Akt(E40K) is inducible in primary cortical neurons 
Primary cortical neurons (rat E18) were isolated and transduced with a lentiviral vector 
containing an empty expression vector (pWPI) or an expression vector containing the DD-
Akt(E40K) fusion gene. 4 days post-transduction, cells were treated with 10 µM TMP for 24 
hours and then lysed for western blotting. (A) A representative blot of the expression levels of 
phosphorylated and total DD-Akt(E40K). (B) Average fold induction with TMP treatment. 
N=2 samples per condition. Graphs shows means with SEM. *p < 0.05, **p < 0.01, unpaired 
































to the heterogeneity of the cultures, levels of induction could not be measured through western 
immunoblotting and instead were measured through intensity of immunofluorescence staining 
through ImageJ. The cultures were processed for immunofluorescence staining after 13-15 days 
in vitro, triple-stained for tyrosine hydroxylase (TH) to identify dopaminergic neurons, GFP to 
identify transduced cells, and HA to identify levels of DD-Akt(E40K). Cultures were then 
imaged using an upright fluorescence microscope. Resulting fluorescent images exhibit a visible 
increase in HA fluorescence intensity (Figure 3.10). Dopaminergic neurons exhibiting dual 
fluorescence signals for both GFP and TH were chosen for quantification of HA fluorescence 
levels using ImageJ. Quantification of one experiment with 8 -TMP neurons and 7 +TMP 
neurons exhibiting GFP and TH fluorescence as described above were measured showed a 
significant increase of 1.85-fold ± 0.23 (p < 0.005 vs.-TMP) in HA fluorescence intensity within 
neurons treated with TMP (Figure 3.11), thus demonstrating that the levels of DD-Akt(E40K) 
can be successfully controlled by TMP in primary dopaminergic neurons.  
Due to the heterogeneous nature of the dopaminergic cultures, it was possible to 
determine the levels of DD-Akt(E40K) in non-dopaminergic cells within the same cultures.  The 
HA fluorescence intensity in randomly chosen, neighboring non-TH stained neurons that 
exhibited GFP expression was quantified through ImageJ (Figure 3.12). Interestingly, the level 
of HA fluorescence intensity observed in non-dopaminergic cells in the absence of TMP was on 
average 3.5-fold lower than in dopaminergic neurons at 8.5 ± 1.4 A.U. in non-dopaminergic cells 
compared to 30.3 ± 4.4 A.U. in dopaminergic neurons (N=12 non-TH neurons, N=8 TH+ 
neurons, one independent experiment). This was in spite of the observation that the absolute HA 
fluorescence intensity reached with TMP remained the same across neuronal type at 51.7 ± 5.9 
A.U. in non-dopaminergic cells and 56.1 ± 5.6 A.U. in dopaminergic neurons. As a result, the 
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fold-induction of DD-Akt(E40K) in non-dopaminergic cells was found to be higher at 6.1-fold 
compared to 1.9-fold in dopaminergic neurons. These results indicate that basal levels of DD-
Akt(E40K) are higher in dopaminergic neurons than neighboring non-dopaminergic cells within 
the same cultures, even though the absolute levels of DD-Akt(E40K) expression reached with 




Figure 3.10: TMP increases DD-Akt(E40K) protein levels in primary dopaminergic 
neurons 
Primary ventral midbrain cultures were isolated from rat pups P0-3 and seeded on a glial 
layer. Neurons were transduced with a lentiviral vector containing an expression vector 
with the DD-Akt(E40K) fusion gene. 6-10 days post-transduction, cultures were treated 
with 10 µM TMP for 4 days and then processed for immunofluorescence. Cultures were 
stained for TH to identify dopaminergic neurons, GFP to identify transduced cells, and HA 

















 Potential Strategies to Reduce Basal Levels of the DD-Akt(E40K) System 
 To address the potential issues of basal DD-Akt(E40K) activity in absence of TMP, we 
pursued several different strategies. One of our colleagues, Dr. Roger Lefort, acquired 
preliminary data suggesting that adding a second DD domain to a different protein of interest 
further reduced basal levels of the protein in absence of TMP (personal communication). 
Additionally, because DD-YFP had been demonstrated to have much higher fold induction than 
DD-Akt(E40K), reaching approximately 65-fold [191], and the Akt protein is much larger at 60 
kDa compared to YFP at 26.4 kDa, we considered the possibility that the DD domain is not able 






































Figure 3.12: DD-Akt(E40K) has higher 
basal levels in dopaminergic neurons 
HA fluorescence intensity was measured in 
transduced (GFP+) neurons using ImageJ. 
Dopaminergic vs. non-dopaminergic neurons 
were identified via TH staining. Graph is 
mean with SEM. N = 7-8 neurons measured 
for TH+ conditions, 12-14 neurons measured 
for non-TH conditions. *p < 0.05: TH, -TMP 
vs. + TMP; ****p < 0.0001: non-TH, -TMP 
vs. + TMP; #p < 0.05: TH, -TMP vs. non-
TH, -TMP, 2-way ANOVA. 
 
 
Figure 3.11: DD-Akt(E40K) is 
inducible in primary 
dopaminergic neurons 
HA fluorescence intensity was 
measured in identified transduced 
dopaminergic neurons using 
ImageJ. The relative fluorescence 
intensity was then quantified. **p 
< 0.005, unpaired t-test +TMP vs. -
TMP conditions. Graph shows 
means with SEM. N = 8 neurons in 
-TMP conditions, 7 neurons in 
+TMP conditions. 
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to become fully unstable in the absence of TMP due to close proximity and hindrance by the Akt 
protein. Although the DD-Akt(E40K) protein contains a 3-amino acid linker (Arg-Ala-Cys) 
between the DD domain and HA-tagged Akt(E40K), it is possible that this linker is not flexible 
enough to permit full destabilizing function of the DD domain. It is interesting to note that the 
Wandless group did utilize glycine linker chains to separate the DD domain and YFP domains 
when spliced internally to the YFP protein (YFPN-DD-YFPC) [191]. The inclusion of a glycine 
linker appeared to improve inducibility to about 10-fold induction compared to 7-fold induction 
without a glycine linker, thus suggesting that flexibility of linker chains may improve the 
destabilizing function of the DD domain [191]. 
 Thus, to determine whether 1) a second DD domain, and 2) a flexible linker could reduce 
basal levels of DD-Akt(E40K), we created constructs with an additional DD domain at the N-
terminus of DD-Akt(E40K) using glycine linker sequences (Gly-Gly-Gly-Gly-Ser) of various 
lengths (Figure 3.13).  
 
It was important that the addition of the second DD domain did not change the absolute 
 
 

























levels of Akt(E40K) reached when treated with TMP because levels of active Akt with TMP-
mediated stabilization would need to remain high for potential pro-survival effects. In other 
words, we wanted to ensure that any strategy to lower basal levels did not also lower induction 
levels that were reached with TMP treatment. Thus, we measured the fold-induction achieved by 
the double DD domain constructs in HEK293 cells (Figure 3.14). If the basal levels were 
reduced with the second DD domain and the “on” levels of Akt(E40K) with TMP treatment 
remained the same, the fold induction should increase. Interestingly, the fold induction levels did 
not appear to change with the addition of the second DD domain, with the exception of (DD-
G4S)x2-Akt(E40K) vs. DD-Akt(E40K) at the pAkt308 site (2-way ANOVA with multiple 
comparison). These data indicate that the second DD domain was not able to achieve both lower 




Figure 3.14: Adding a second DD domain does not improve fold induction or basal activity 
HEK293 cells were transfected with constructs to overexpress single DD domain Akt(E40K) 
or double DD domain Akt(E40K) with various linker combinations. Cells were treated with 
10 µM TMP for 24 hours and then lysed for western blotting. Protein expression levels were 
quantified and normalized to ERK as a loading control. Fold induction was calculated as a 
ratio of protein levels with TMP treatment divided by protein levels without TMP treatment. 
Graph shows means with SEM. N = 2 independent experiments. *p < 0.05 vs. DD-
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Another consideration to optimize basal levels of the DD-Akt(E40K) system is the 
membrane binding of the mutant Akt. As discussed in Section 3.1, the E40K mutation within the 
PH domain of Akt increases its membrane affinity, thus increasing membrane binding and 
phosphorylation of Akt. Although the FKBP12-derived DD system had been validated to 
inducibly stabilize transmembrane proteins [192], the DHFR-derived DD system has only been 
applied to non-membrane bound proteins in the literature. Thus, it is conceivable that the 
increased membrane binding of Akt(E40K) may impede its degradation when not treated with 
TMP and increase the basal levels of the protein. To determine whether the PH domain mutation 
interferes with DD-mediated degradation, a construct with no PH mutation, DD-Akt(WT), was 
created. HEK293 cells were transfected with the WT and E40K constructs and treated with TMP 
for 24 hours to compare and determine any differences in basal protein levels or induction that 
may be caused by the mutation (Figure 3.15). There was no difference detected in either total 
levels of Akt or phosphorylated Akt between WT or the E40K proteins when untreated with 
TMP (n.s., 2-way ANOVA with multiple comparisons), indicating that increased membrane 
affinity does not impede DD-mediated degradation. As expected, the levels of phosphorylated 





 Characterization of DD-Akt(E40K) Regulation 
Once TMP-mediated DD-Akt(E40K) inducibility was established in multiple cell 
systems, and optimization strategies of basal levels was attempted, the next important step to test 
this system’s full applicability as a tool to control Akt levels was to further characterize the 
 
Figure 3.15: Increased membrane affinity does not affect DD-mediated destabilization 
HEK293 cells were transfected with DD constructs with WT Akt or Akt(E40K). Cells were treated 
with 10 µM TMP for 24 hours and then lysed for western blotting. Protein expression levels were 
quantified and normalized to ERK as a loading control. Fold induction was calculated as a ratio of 
protein levels with TMP treatment divided by Akt(WT) protein levels without TMP treatment. Graph 
shows means with SEM. N = 3 replicate samples per condition. ****p < 0.0001; n.s. vs. DD-Akt(WT) 
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regulation of DD-Akt(E40K) by TMP.  
One of the potential advantages of the DD system is its dose-responsive inducibility that 
is mediated by the stabilizing ligand. As such, the levels of stabilized protein should depend on 
the levels of TMP available to bind and stabilize the DD-fusion protein. Thus, we investigated 
whether the DD-Akt(E40K) fusion protein exhibited dose-responsive behavior to TMP 
treatment. HEK293 cells were transiently transfected with DD-Akt(E40K) expression vectors 
and subsequently treated with different doses of TMP, ranging from 10 nM to 100 µM for 24 
hours. Cells were then lysed for protein extraction and Akt protein levels were quantified 
through immunoblotting. The DD-Akt(E40K) protein was found to be dose-responsive to TMP, 
reaching half-maximal induction by 50-100 nM and maximal induction by 500 nM (Figure 3.16).  
An additional advantage of the DD system is its ability to rapidly permit elevation of 
protein levels, due to constitutive expression and degradation of the protein as well as the 
reversibility of the induction. To better determine the kinetics of induction, HEK293 cells were 
transiently transfected with DD-Akt(E40K) and treated with 10 µM TMP for different lengths of 
time. Induction of DD-Akt(E40K) by TMP was found to steadily increase across a period of 24 
hours (Figure 3.17A). Additionally, transfected cells were treated with 10 µM TMP for 24 hours 
and then washed with 1X PBS 3 times at different time points to determine the length of time 
required for reversal of induction. When the total levels of DD-Akt(E40K) protein were 
quantified, reversal of induction was found to happen as a steady decrease of DD-Akt(E40K) 
protein levels, with an estimated 30 hours required for half reversal. At least 48 hours were 
required for DD-Akt(E40K) protein levels to return close to baseline (Figure 3.17B). These 
results clearly demonstrate that levels of DD-Akt(E40K) can be induced by TMP and reversed 
with removal of TMP to baseline in vitro, a potentially important characteristic for the utility of 
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Figure 3.16: DD-Akt(E40K) is dose-responsive to TMP treatment 
HEK293 cells were transfected with DD-Akt(E40K) and treated with differing doses of TMP 
for 24 hours. Cells were then lysed and processed for immunoblotting. (A) This representative 
blot shows a clear increase in levels of DD-Akt(E40K), both phosphorylated and total, with 
increasing doses of TMP. The top band represents DD-Akt(E40K) and the bottom represents 
endogenous Akt, as indicated. (B) DD-Akt(E40K) levels were quantified and normalized to a 
loading control. The dose responsive range of DD-Akt(E40K) was found to be between 10 
nM and 500 nM. Graph shows means with SEM. N=3-4 independent experiments. 
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 DD-Akt(E40K) Regulation Under Conditions of Reduced PI3K Signaling 
 As various studies have suggested that PI3K signaling is impaired or dysfunctional in PD 
[154, 155], we strove to understand the induction of the DD-Akt(E40K) system under conditions 
in which PI3K has been inhibited.  
HEK293 cells were transiently transfected with DD-Akt(E40K) and pre-treated with 10 
μM TMP for 24 hours before adding 50 μM PI3K inhibitor LY294002 for 24 hours. Importantly, 
although the overall levels of active DD-Akt(E40K) were suppressed by about 5-fold when PI3K 
was inhibited, the overall fold-induction by TMP treatment was maintained, indicating that the 
inducibility of the system is not compromised under conditions with little to no PI3K signaling 
(Figure 3.18). Furthermore, the addition of the inhibitor was enough to eliminate detectable 
endogenous active Akt, as measured by pAkt308 and pAkt473 (Figure 3.19). However, the 
 
Figure 3.17: DD-Akt(E40K) is steadily induced across 24 hours and is reversible 
(A) HEK293 cells were transfected with DD-Akt(E40K) and treated with 10 μM TMP for 
different time points. Graph shows means with SEM. N = 2-4 independent experiments. (B) 
Cells treated with 10 μM TMP for 24 hours were washed to remove TMP in the medium at 
different time points. Protein levels of phosphorylated and total DD-Akt(E40K) were 
analyzed to determine time course reversal. Data shown are from one independent 
experiment. 
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activity of DD-Akt(E40K) was maintained to an average of 67% of endogenous pAkt308 levels 
under normal (with no PI3K inhibition) conditions and 45% of endogenous pAkt473 levels under 
normal (with no PI3K inhibition) conditions (Figure 3.19). These results demonstrate that DD-
Akt(E40K) can maintain inducibility under conditions involving very low PI3K signaling, which 
is again important for applications as a therapeutic strategy in PD. 
 
 
Figure 3.18: DD-Akt(E40K) inducibility persists with inhibited PI3K signaling 
HEK293 cells were transfected with DD-Akt(E40K) and pre-treated with 10 μM TMP for 24 
hours before adding 50 μM LY294002. Protein levels of phosphorylated and total Akt were 
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3.3:  Discussion 
 In this chapter, we report the creation of an innovative method for post-translational 
control of Akt levels using a DHFR-derived destabilizing domain. The addition of this 
destabilizing domain to a mutant Akt with high activity levels (Akt(E40K)) gives rise to a fusion 
protein that is constitutively expressed and degraded. This technique has the unique advantage of 
permitting control of DD fusion protein levels via a commonly used antibiotic, Trimethoprim 
(TMP), that is inexpensive and membrane permeable. Here we show successful TMP-mediated 
inducibility in a variety of cell types, including human embryonic kidney cells, neuronal PC12 
cells, rat primary cortical neurons, and dopaminergic neuronal cultures (Section 3.2.1). This 
induction was demonstrated to be dose-responsive to TMP and reversible (Section 3.2.3), as well 
as able to maintain inducibility and activity in conditions with suppressed PI3K signaling 
 
 
Figure 3.19: DD-Akt(E40K) activity persists despite suppressed PI3K activity 
HEK293 cells were transfected with DD-Akt(E40K) and pre-treated with 10μM TMP for 
24 hours before adding 50μM of LY294002. Protein levels of phosphorylated Akt were 
analyzed through immunoblotting. The protein band intensity levels were calculated as a 
percent of endogenous pAkt signaling under control conditions. The mean of expression 
levels in each condition is indicated below each bar. Graphs are means with SEM. N=3 
independent experiments. 
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 Our data reveal an interesting finding regarding the levels of DD-Akt(E40K) induction 
across cell types. In HEK293 cells, fold-induction levels of the phosphorylated form of DD-
Akt(E40K) at Ser473 and total DD-Akt(E40K) were found to be roughly equivalent, while 
phosphorylated DD-Akt(E40K) at Thr308 was slightly higher (Figure 3.6). However, in a 
neuronal cellular context (neuronal PC12 cells and primary cortical neurons), the fold-induction 
levels of phosphorylated DD-Akt(E40K) appeared to be much lower than fold-induction levels 
of total DD-Akt(E40K) (Figures 3.7 and 3.9). This phenomenon directly implies that there exists 
some difference in the proportion of total Akt available that is phosphorylated across the 
different cell types tested. Potential reasons for this distinction are two-fold: first, there may be 
lower efficiency of the Akt phosphorylation machinery in neuronal PC12 cells and cortical 
neurons than in HEK293 cells such that with a certain increase in total Akt, a smaller proportion 
is phosphorylated in the cell; second, the levels of phosphorylated Akt within the cell may be so 
tightly regulated that there is a cap on the level of increase a cell will permit, perhaps based on 
upstream phosphatase activity, and beyond that cap, there will be no further increase in 
phosphorylated Akt regardless of further increases in total Akt. Our data suggests that the second 
explanation may be more plausible because the overall fold-increases of total DD-Akt(E40K) 
were drastically increased from 2.6-fold in HEK293 cells to 11.9-fold in neuronal PC12 cells, but 
the increases in phosphorylated DD-Akt(E40K) were different in inconsistent directions between 
HEK293 cells and neuronal PC12 cells. However, it is difficult to conclusively deny the former 
explanation for the observed distinctions in fold-induction across cell types with the data 
observed, because the fold-induction for phosphorylated DD-Akt(E40K) at the serine site were 
highest in neuronal PC12 cells than in HEK293 cells or primary cortical neurons – this may 
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indicate that increases in total DD-Akt(E40K) did lead to some increase in phosphorylated DD-
Akt(E40K), though we cannot be sure if this increase was equally or less proportional with total 
Akt increases up to the aforementioned “cap”. Furthermore, our data cannot distinguish whether 
this difference could be attributed to either a difference in cell type (i.e., neuronal versus kidney) 
or in species of animal that the cell line is sourced from (i.e., rat versus human). Further 
investigation into this phenomenon may lead to insights about differences in endogenous Akt 
activation levels dependent on cell type. 
 One of the potential weaknesses of our DD-Akt(E40K) system lies in the basal levels of 
the protein present even without TMP treatment. We believe this may be due to the nature of the 
degradation domain-based inducible system, wherein the protein of interest is constitutively 
expressed and degraded by the proteasome such that there must exist a steady state basal level of 
the protein even without the stabilizing ligand. In investigating levels of basal DD-Akt(E40K) 
across dopaminergic neurons and non-dopaminergic cells, we came across an intriguing finding 
of greater than 250% higher basal DD-Akt(E40K) levels detected in dopaminergic neurons than 
non-dopaminergic neurons (Figure 3.12). This finding leads to the interesting question of 
whether protein degradation activity is different depending on cell type. Given the literature 
supporting dysfunction of the ubiquitin-proteasome system as a contributing factor in 
Parkinson’s disease [235, 236] and reports of lower proteasome activity in the substantia nigra 
compared to other brain regions even in non-disease contexts [237, 238], it is very likely that the 
observed higher basal levels of DD-Akt(E40K) in dopaminergic neurons are due to impaired or 
lower proteasomal activity in dopaminergic neurons, which would impact the proteasome-
dependent degradation of DD-fusion proteins [191]. Although the observed differences in basal 
DD-Akt(E40K) levels in these cultures is statistically significant, this intriguing result may merit 
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further investigation with larger numbers of neurons. Results could potentially lead to insights 
into selective vulnerability of dopaminergic neurons in Parkinson’s disease. 
 Finally, our data on DD-Akt(E40K) signaling in the context of impaired PI3K activity 
demonstrates the maintenance of inducible control with TMP in these conditions, enough to 
reach 45-67% of control endogenous pAkt levels (under PI3K non-inhibited conditions) (Figure 
3.19). This finding is important because it establishes that the DD-Akt(E40K) inducible system 
will remain reliably regulatable, even within Parkinson’s disease contexts where PI3K signaling 
is reported to be decreased [154, 155]. The question remains whether 45-67% of endogenous Akt 
signaling is sufficient to promote Akt-mediated survival of cells. We will explore this question in 






Chapter 4: Physiological Activity of DD-Akt(E40K) in vitro 
4.1:  Introduction 
The previous chapter established DD-Akt(E40K) as a reliably inducible Akt construct in 
multiple cellular contexts that can partially maintain its activity under conditions with low or 
absent PI3K signaling. The next step in our work was to determine whether DD-Akt(E40K) can 
show inducible physiological functions. Our data in this chapter demonstrate that DD-Akt(E40K) 
can reliably and inducibly phosphorylate a known downstream substrate of Akt, FoxO4 [117] in 
293 cells, and can promote survival in a neuronal cell line against various cellular insults.  
FoxO4 is a member of the FoxO family of transcription factors, which have been widely 
studied for their effects on cell cycle regulation, metabolism, and survival [239]. The FoxO 
family has also been implicated as tumor suppressors, as chromosomal translocations involving 
the genes encoding FoxOs have been found to occur in acute myeloid leukemia and 
rhabdomyosarcomas [240]. Additionally, FoxO4 has specifically been shown to mediate cell 
cycle and apoptosis through upregulation of cell cycle protein p27 Kip1 and proapoptotic gene 
Bim [241-243]. As mentioned above, FoxO4 is a direct substrate of Akt, with PI3K-Akt 
signaling demonstrated to negatively regulate FoxOs, through phosphorylation by Akt, which 
sequesters the transcription factors with 14-3-3, thus impairing its nuclear translocation and 
upregulation of proapoptotic genes [120, 244, 245]. This relationship is evolutionarily conserved, 
thus implying its importance as a general regulatory mechanism in cells [239]. 
As discussed in detail in Chapter 1, Akt signaling is regarded to be a critical signaling 
pathway with a variety of downstream physiological effects ranging from cell growth and 
metabolism to survival [117]. With the reported involvement of suppressed Akt signaling in a 
variety of Parkinson’s disease (PD) models, we sought to verify the physiological effects of DD-
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Akt(E40K) in various models of suppressed Akt signaling including growth factor removal 
(serum deprivation) and PD toxin models. 
 To carry out our physiological studies in a relevant neuronal context, we employed the 
PC12 cell line. The PC12 cell line was derived from a transplantable rat adrenal 
pheochromocytoma and has been used extensively as a cellular model for pathological 
conditions including neurodegeneration [224, 246]. While in the naïve state, PC12 cells depend 
on serum-supplemented medium, and removal of serum from the medium leads to apoptotic 
death. PC12 cells can be differentiated into nondividing sympathetic-neuron like cells with the 
addition of nerve growth factor (NGF). Differentiated PC12 cells exhibit morphologies 
consistent with neuronal cells, including extension of axonal processes [224]. Importantly, 
differentiated PC12 cells are sensitive to PD mimetic toxins such as 6-hydroxydopamine (6-
OHDA) and 1-methyl-4-phenylpyridinium (MPP+), among others [247, 248]. Both 6-OHDA and 
MPP+ are mitochondrial toxins that can induce cellular degeneration within 24-48 hours of 
exposure.  
 In this chapter, we explore the ability of DD-Akt(E40K) to inducibly phosphorylate a 
known downstream substrate involved in survival signaling and its ability to promote cellular 
survival in various cellular stress models, including serum deprivation and toxin-based PD 
models. The research presented here demonstrates that the expression of DD-Akt(E40K) can 
protect cellular models against stress conditions that induce apoptosis. Importantly, the results 
also demonstrate that the physiological effects on survival can be controlled by the presence of 






4.2:  Results  
 Downstream Signaling of DD-Akt(E40K) 
To better understand the signaling of DD-Akt(E40K) and validate that the fusion protein 
maintains its function as a kinase, we investigated the effect of DD-Akt(E40K) induction on a 
known Akt substrate, FoxO4 [117]. As mentioned in Section 4.1, FoxO4 is a transcription factor 
of the FoxO family of proteins that is known to be a mediator of apoptosis through upregulation 
of proapoptotic gene targets such as BH3-only protein BIM [243]. Akt blocks FoxO-mediated 
transcription of proapoptotic genes through phosphorylation of the FoxO protein, which leads to 
nuclear exit and sequestration of FoxO in the cytosol [117].  
HEK293T cells were transfected with DD-Akt(E40K) expression vector and then treated 
with 10 μM TMP for 24 hours. Cells were then lysed to isolate protein and the levels of 
phosphorylated FoxO4 (pFoxO4) at the Akt phosphorylated site, S193, were analyzed through 
immunoblotting. Results demonstrate a 2.2-fold ± 0.95 elevation of pFoxO4 (p ≤ 0.01 vs -TMP, 
1-way ANOVA) with the induction of DD-Akt(E40K), indicating that TMP can stabilize the 
fusion protein and permit accumulation of active Akt within the cell, which subsequently 
phosphorylates an Akt substrate important for cell survival (Figure 4.1). Importantly, there was 
no significant elevation of pFoxO4 in conditions with DD-Akt(E40K) transfection but without 
TMP treatment, thus indicating that basal expression levels of DD-Akt(E40K) were not 
sufficient to significantly elevate phosphorylated downstream substrates. Additionally, there was 
no elevation of total FoxO4 observed. This is an important result that shows that the addition of 






 DD-Akt(E40K) Inducibly Protects Naïve PC12 Cells Against Serum Deprivation 
 As mentioned above, naïve, undifferentiated PC12 cells rely on the presence of serum in 
the medium for survival. When serum is removed from the medium, PC12 cells begin to undergo 
apoptosis due to the removal of growth factor signaling. Thus, we used this model to investigate 
potential physiological effects of inducible DD-Akt(E40K) on promoting survival. Because Akt 
signaling has been well-characterized, particularly with regards to its crucial role as a mediator 
of growth factor signaling and cellular survival, we anticipated that DD-Akt(E40K) would have 
similar pro-survival effects in this model when induced with TMP, but not in the absence of 
TMP. 
 Naïve PC12 cells were seeded onto collagen-coated dishes and transduced with a 
 
Figure 4.1: DD-Akt(E40K) phosphorylates downstream substrate pFoxO4 
HEK293 cells were transfected with DD-Akt(E40K) and treated with 10μM TMP for 24 
hours. (A) Protein levels of phosphorylated FoxO4 S193 were analyzed to determine any 
induction of pFoxO4 with increase in active DD-Akt(E40K). Graph is mean with SEM. N = 
9 independent experiments (7 experiments with no serum, 2 experiments with serum). 
**p<0.01 compared with DD-Akt(E40K) - TMP condition, #p<0.05 compared with empty 
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lentiviral vector containing an IRES-overexpression construct to co-express DD-Akt(E40K) and 
GFP. After 4 days, the cultures were treated with 10 μM TMP, or NGF as a positive control, for 
24 hours to induce DD-Akt(E40K) expression. Subsequently the cells were washed off the 
dishes, washed with serum-free medium, centrifuged to remove all medium, and replated with 
serum-free medium. After 16-24 hours of serum deprivation when approximately 50% of the 
cells have undergone apoptosis, the cells were then lysed to analyze survival through 
quantification of viable nuclei. Quantifications were normalized to cells treated with NGF as a 
positive control. 
The results reveal a statistically significant protection effect of TMP-induced DD-
Akt(E40K) with 92.4% ± 13.4% survival compared to 56.7% ± 1.8% survival in cultures 
transduced with an empty vector control and not treated with NGF or 60.7% ± 8.0% survival in 
cultures transduced by DD-Akt(E40K) but not induced by TMP treatment (Figure 4.2). 
Importantly, the level of protection by induced DD-Akt(E40K) was almost to equivalent to 
protection found with NGF-treated cells, indicating that DD-Akt(E40K) with TMP treatment is 
capable of protection against serum deprivation-induced apoptosis at levels comparable to a 
growth factor (Figure 4.2). The transduction efficiency across independent experiments was 
found to be approximately 60%, as determined through immunofluorescence staining of GFP-
positive cells. Thus, if transduction efficiency had been 100%, one could potentially observe a 
survival rate even higher than that found with NGF treatment. Importantly, there was no 
additional protective effect found in cells expressing DD-Akt(E40K) but not treated with TMP, 






 DD-Akt(E40K) Inducibly Protects Neuronal PC12 Cells in PD Toxin Models 
 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-OHDA are neurotoxins that 
can cause selective degeneration of dopaminergic neurons when administered in vivo. MPTP 
itself is not toxic, but its lipophilic properties allow it to cross the blood brain barrier where it can 
subsequently be metabolized by glial cells into the toxic cation, 1-methyl-4-phenylpyridinium 
(MPP+). Although the precise mechanism of action has been debated, both MPP+ and 6-OHDA 
have been shown to be inhibitors of mitochondrial complex I and promote the formation of 
reactive oxygen species that lead to degeneration of catecholaminergic neurons [68]. The 
selectivity of the MPP+ and 6-OHDA as well as the resulting mitochondrial dysfunction and 
oxidative stress that potentially mimic features of PD thus make these toxins useful in in vivo 
models that replicate certain features of classic Parkinsonism including degeneration of the 
nigrostriatal pathway and motor impairment [68]. Additionally, MPP+ and 6-OHDA can induce 


































































Figure 4.2: DD-Akt(E40K) protects 
against serum deprivation 
Naïve PC12 cells were transduced 
with a lentiviral vector for 
overexpression of DD-Akt(E40K). 
Cultures were pre-treated with 10 
μM TMP for 24 hours and then 
washed and replated with serum-free 
medium. After 16-24 hours of serum 
deprivation, cells were lysed for 
quantification of viable nuclei to 
measure survival. Average 
transduction efficiency was 60%. 
Graph shows means with SEM. *p < 
0.05, n.s. vs. EV-NGF; 2-way 





[247, 248].  
 To determine whether DD-Akt(E40K) can inducibly protect neuronal PC12 cells against 
these PD mimetic toxin insults, we used a lentiviral vector to transduce cultures with an 
overexpression vector containing the DD-Akt(E40K) gene. Cultures were then pretreated with 10 
μM TMP for 24 hours before adding varying concentrations of MPP+ or 6-OHDA.  
 TMP-mediated induction of DD-Akt(E40K) was found to significantly protect neuronal 
PC12 cells against MPP+ toxin insult with 87% ± 6.8% survival observed in TMP-treated cells 
compared to 62% ± 2.9% survival in cells expressing an empty vector control (p ≤ 0.01, 2-way 
ANOVA) or 60% ± 2.1% in cells expressing DD-Akt(E40K) but not treated with TMP (p ≤ 0.01, 
2-way ANOVA) (Figure 4.3). No protection was observed when cultures were not treated with 
TMP, indicating that any basal expression of DD-Akt(E40K) was not enough to impact survival 
rates. The transduction efficiency for these cultures was found to be approximately 75%, as 
determined through immunofluorescence staining of GFP-positive cells. Thus, had transduction 
efficiency been 100%, the expected survival with TMP-induced DD-Akt(E40K) observed in the 




 DD-Akt(E40K) was found to inducibly protect neuronal PC12 cells against 6-OHDA 
toxin as well (Figure 4.4). This protective effect was present even at higher (150 μM) doses of 6-
OHDA with 74% ± 1.8% survival observed with TMP-induced DD-Akt(E40K) compared to 
54% ± 4.7% in cultures with an empty vector control (p ≤ 0.001, 2-way ANOVA) or 61% ± 
4.9% in cultures expressing DD-Akt(E40K) but not stabilized with TMP (p ≤ 0.05, 2-way 
ANOVA). The magnitude of protection was slightly lower than was observed at 100 μM 6-
OHDA with 88% ± 5.4% survival in cells with induced DD-Akt(E40K) compared to 65% ± 
3.1% in cells with an empty vector control (p ≤ 0.001, 2-way ANOVA) or 66% ± 1.1% in cells 
with uninduced DD-Akt(E40K) (p ≤ 0.001, 2-way ANOVA), but the proportional increase in 
survival with TMP-mediated induction of DD-Akt(E40K) was comparable at 35-37%. Again, it 
is important to note that our findings did not show any protective effect in conditions with DD-
 
Figure 4.3: DD-Akt(E40K) protects against MPP+ 
Neuronal PC12 cells were transduced with a lentiviral vector for overexpression of DD-
Akt(E40K). Cultures were pre-treated with 10 μM of TMP for 24 hours before the addition 
of 0.25 mM of MPP+. After 18-24 hours of MPP+ treatment, cells were lysed for 
quantification of viable nuclei to measure survival. Graph shows means with SEM. **p < 
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Akt(E40K) expression but no TMP treatment, indicating that any basal expression that may be 
present in the cells was not enough to induce a physiological effect on survival. Although the 
transduction efficiency for these experiments was not directly determined, if we assume a similar 
efficiency of 75% as that observed in the MPP+ experiments with the same culture type, the 
corrected survival with TMP-induced DD-Akt(E40K) becomes 96% at the lower dose of 6-
OHDA and 81% at the higher dose of 6-OHDA.  
 
Importantly, treatment with TMP by itself was found to be insufficient for protection 
against 6-OHDA toxin insult (Figure 4.5). This finding confirms that any protective effect 
observed with DD-Akt(E40K) and TMP treatment is not due to any off-target effects of TMP, 
but rather the induction of active DD-Akt(E40K) within the cells.  
 
Figure 4.4: DD-Akt(E40K) protects against 6-OHDA 
Neuronal PC12 cells were transduced with a lentiviral vector for overexpression of DD-
Akt(E40K). Cultures were pre-treated with 10 μM TMP for 24 hours before the addition of 
100 μM or 150 μM 6-OHDA. After 18-24 hours of 6-OHDA treatment, cells were lysed for 
quantification of viable nuclei to measure survival. Graph shows means with SEM. ***p < 
0.001 vs. –TMP; *p < 0.05 vs. –TMP; ### p < 0.001 vs. Empty Vector; n.s. vs. Empty 
Vector; 2-way ANOVA. N = 3 independent experiments. 
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 DD-Akt(E40K) Induction Persists With 6-OHDA Toxin Treatment 
Suppression of Akt has been shown in various models of in vitro and in vivo PD as well 
as in the disease itself [138, 152, 162-164, 166]. Thus, it was important to determine whether 
DD-Akt(E40K) activation can persist in such PD models known to have dysfunctional Akt 
signaling. Neuronal PC12 cells were analyzed in a pilot experiment for protein expression of 
phosphorylated and total Akt under conditions of 6-OHDA treatment with DD-Akt(E40K) 
present (Figure 4.6). The protein levels indicate that DD-Akt(E40K) induction can indeed persist 
with the addition of 6-OHDA toxin, even at higher doses that can suppress endogenous Akt 
signaling. Furthermore, when compared to the average endogenous pAkt levels under control (no 
toxin) conditions, the levels of phosphorylated DD-Akt(E40K) at the threonine site (T308) when 
induced with TMP exceeded endogenous pAkt308 levels in control conditions (no toxin) by 
approximately 95% and remained approximately 35% higher than endogenous pAkt308 levels 
 
Figure 4.5: TMP by itself is not protective against 6-OHDA 
Neuronal PC12 cells were pre-treated with 10 μM TMP for 24 hours before the addition of 
100 μM or 150 μM 6-OHDA. After 18-24 hours of 6-OHDA treatment, cells were lysed for 
quantification of viable nuclei to measure survival. Graph is mean with SEM. No significance 
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even when treated with the higher dose of 6-OHDA (Figure 4.7). This result is consistent with 
the protective effects observed in the survival assays (Figure 4.4). The levels of phosphorylated 
DD-Akt(E40K) at the serine site (S473) appeared to be more suppressed by 100 µM 6-OHDA 
toxin treatment and reached approximately 55% of control endogenous pAkt473 expression 






Figure 4.6: DD-Akt(E40K) signaling persists in the presence of 6-OHDA 
Neuronal PC12 cells were transduced with a lentiviral vector for overexpression of DD-
Akt(E40K). Cultures were pre-treated with 10 μM TMP for 24 hours before the addition of 
100 μM or 150 μM 6-OHDA. After 8 hours of 6-OHDA treatment, cells were lysed for 
protein immunoblotting analysis. “DD-Akt” indicates protein bands for DD-Akt(E40K) and 
“Endo-Akt” indicates protein bands for endogenous Akt. 
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4.3:  Discussion 
Previous studies have established Akt signaling as a potential therapeutic target for 
Parkinson’s disease due to its neuroprotective and neurorestorative features [138, 139]. However, 
precisely due to Akt’s promotion of cell growth, survival, and proliferation, a constitutively 
active form of Akt is not a viable therapeutic tool because it can promote cancer and potentially 
promote extraneous sprouting of neuronal projections. Therefore, Akt as a therapeutic 
intervention must be one in which the activity can be controlled, ideally with a drug. We have for 
the first time to our knowledge, demonstrated that an inducible form of Akt can exhibit 
neuroprotective effects that are controllable through a commonly used antibiotic, TMP, within 
Akt-deficient models and in vitro PD models.  
Importantly, our findings demonstrate that DD-Akt(E40K) is indeed catalytically active 
and able to phosphorylate a known Akt substrate, FoxO4, as a potential mediator of the 
 
Figure 4.7: DD-Akt(E40K) retains activity in the presence of 6-OHDA 
Neuronal PC12 cells were transduced with a lentiviral vector for overexpression of DD-
Akt(E40K). Cultures were pre-treated with 10 μM of TMP for 24 hours before the addition of 
100 μM or 150 μM 6-OHDA. After 8 hours of 6-OHDA treatment, cells were lysed for 
protein immunoblotting analysis. Densitometry analysis of the blot from Figure 4.6 is shown 
here. (A) pAkt308 protein levels and (B) pAkt473 protein levels were normalized to GAPDH 
as a loading control and calculated as a proportion to average endogenous pAkt levels under 
control (no toxin) conditions. 
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neuroprotective effects observed with DD-Akt(E40K) induction. As always, one must keep in 
mind the less than 100% transfection efficiency achieved, which implies that increases in 
phosphorylated FoxO4 we observed may be even higher. Importantly, our results demonstrate 
that there was no significant enhancement of phosphorylated FoxO4 without TMP (Figure 4.1). 
With the observed maintenance of active DD-Akt(E40K) levels in the cell during insult with a 
PD mimetic toxin, as shown in Figure 4.6, and the findings that phosphorylation of FoxO4 
increase with induction of DD-Akt(E40K) in Figure 4.1, we believe that phosphorylation and 
subsequent cytosolic sequestration of FoxO4 may be involved as an effector of the protective 
effect observed in the cell death models presented in this chapter. It is also likely that other 
known Akt substrates may be involved, particularly those known to be part of the apoptotic 
pathway, such as BAD, BIM, and other FoxO proteins including FoxO3A. However, perhaps 
due to lack of 100% transfection efficiency, we were not able to detect reliable increases in 
phosphorylation of other signaling proteins downstream of Akt, including GSK3β, PRAS40, 
FoxO1, FoxO3a, and p70S6K (data not shown). 
The serum deprivation model is a relatively straightforward model of apoptosis induced 
by removal of growth factor and therefore deficient PI3K/Akt signaling. Thus, it was anticipated 
that the induction of DD-Akt(E40K) would result in full protection against cell death in this 
model. Importantly, the degree of protection observed with induced DD-Akt(E40K) was similar 
to that of protection by NGF. In other words, the protective effect by active DD-Akt(E40K) is 
approximately equivalent to the protective effect by trophic factors, which would presumably 
constitute the “best” potential result in rescue of survival in a serum deprivation model. If one 
were to take the incomplete transduction efficiency into consideration, it is possible that 
induction of DD-Akt(E40K) could potentially protect cells to a higher degree than NGF. 
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However, due to right endogenous regulation of the PI3K/Akt signaling pathway activity, there 
may potentially be a cap on the level of protection observed with Akt overactivity. 
Our findings further demonstrate that DD-Akt(E40K) can inducibly protect neuronal 
PC12 cells in PD toxin models of MPP+ and 6-OHDA, with lower levels of surviving cells 
observed with increases doses of toxin, as demonstrated with 6-OHDA (Figure 4.3, Figure 4.4). 
In addition, we found that the proportional increase in survival against 6-OHDA with TMP-
induced DD-Akt(E40K) was comparable at approximately 35-37% regardless of the dose of the 
toxin insult. Importantly, we have demonstrated that the increase in survival is not due to non-
specific effects of TMP treatment (Figure 4.5), strengthening our conclusion that survival effects 
are dependent on DD-Akt(E40K) activity within cultures. For future work, it would be 
interesting to see whether this neuroprotective effect can be corroborated in non-toxin PD 
models, such as models of α-synuclein fibrils [32]. 
As mentioned previously, in all survival experiments presented here, the cultures were 
not transduced completely, which introduces the potential increased survival rates if corrected 
for transduction efficiency. This increase in survival rate can be estimated if one calculates the 
difference in survival between empty vector control (non-toxin) conditions and DD-Akt(E40K) + 
TMP conditions as a proportion of “available survival” and corrects based on known 
transduction efficiencies. By these corrections, 100% transduction efficiencies in neuronal PC12 
cells would translate to almost full protection at approximately 95% total survival achieved by 
TMP-induced DD-Akt(E40K) against MPP+-induced cell death as well as against the lower dose 
of 6-OHDA. It is also important to note that this estimate does not take into account the 
differences in level of protein expression within each cell, which is not reflected in the 
measurement of transduction efficiency. Thus, it is conceivable that full protection with 
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induction of DD-Akt(E40K) is possible in these cell death models with a higher viral titer that 
allows for increase in both proportion of cells transduced as well as protein load per cell. 
Previous investigation has demonstrated the dephosphorylation of Akt following 
treatment with 6-OHDA [152]. Our findings corroborate the previous results and additionally 
show that DD-Akt(E40K) activity can persist despite the suppression of endogenous Akt 
phosphorylation by 6-OHDA (Figure 4.6). Further observation suggests that the Ser473 
phosphorylation site may be more affected by the toxin than the Thr308 site, as the increasing 
dose of 6-OHDA leads to more dephosphorylation of the Ser473 site than Thr308 site. This is 
consistent with and reflective of the PI3K inhibitor experiments in Chapter 3 in which we 
observed that PI3K inhibition suppressed DD-Akt(E40K) phosphorylation with TMP treatment 
to 45% that of endogenous control levels at the Ser473 site, in contrast to 67% at the Thr308 site. 
Although the general mechanisms of activation of Akt by PDK1 and mTORC2 are well 
established, the detailed interplay between the two activators and phosphorylation sites is still 
poorly understood. Our findings indicate that there is a distinction in the behavior of the 
canonical Akt phosphorylation sites in response to cellular stressors. However, the significance 
of this observation is unclear and may merit further study and discussion.  
Finally, our data presented in this chapter reveal that basal levels of DD-Akt(E40K) 
without TMP, which were observed in the findings described in Chapter 3, are not enough to 
increase phosphorylation of a known substrate (FoxO4), and as a result do not enhance the 
biological effects of Akt activity on survival. This is an important finding that supports the 
potential of this inducible system for clinical usage as its basal activity is not enough to induce 
any physiological outcomes of Akt signaling. 
The findings presented in this chapter demonstrate the utility of this inducible Akt system 
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for signaling studies and as a proof of principle for Akt-based therapeutic strategies in 
pathological conditions, specifically within PD. Although the toxin models of PD do not 
perfectly replicate all characteristics of the disease, suppression of endogenous Akt signaling has 
been observed in various PD genetic models as well as post-mortem sporadic PD human brains 
[152]. Our results replicate this suppressive effect of Akt signaling using the PD-mimetic toxin 
6-OHDA (Figure 4.6) and further demonstrate that the induction of DD-Akt(E40K) can reverse 
the total levels of active Akt enough to promote survival in PD toxin models. An interesting next 
step would be to test the protective effect of DD-Akt(E40K) in non-toxin models of PD. One 
model in particular that has come into the field as potentially relevant to disease pathology and 
progression is the α-synuclein fibril model [32-34]. This method would provide a robust non-
toxin PD model to test the use of inducible Akt as a protective agent in Parkinson’s disease.  
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Chapter 5: DD-Akt(E40K) In Vivo 
5.1:  Introduction 
As discussed in Chapter 1, PD is a neurodegenerative disease that is characterized by 
motor deficits associated with degeneration of dopaminergic neurons in a very specific subregion 
of the basal ganglia, called the substantia nigra pars compacta (SNpc). Thus, an ideal therapeutic 
strategy to treat PD would be targeted towards this subset of neurons. In Chapter 3, we 
demonstrated the trimethoprim (TMP)-mediated inducibility of DD-Akt(E40K) in various cell 
culture systems, including dopaminergic neurons. The regulation of DD-Akt(E40K) was found 
to be dose responsive to the administration of TMP and reversible with the removal of TMP from 
the medium. In Chapter 4, we demonstrated the physiological relevance and applicability of the 
DD-Akt(E40K) system as an inducible neuroprotective strategy in PD. Our findings established 
the capability of DD-Akt(E40K) to inducibly protect neuronal PC12 cells against PD mimetic 
toxin insults in culture and potentially achieves this through phosphorylation of the substrate, 
FoxO4. To further validate the DD-Akt(E40K) as a controllable protein expression system with 
potential applications as a PD therapy, we sought to test the regulatable expression of DD-
Akt(E40K) in vivo.  
We chose the adeno-associated virus (AAV) serotype 1 to deliver the DD-Akt(E40K) 
expression vector to the SNpc of mice for a variety of reasons. First, AAV vectors exhibit a 
strong preference for neuronal transduction with AAV1 in particular exhibiting significantly 
more efficient transduction of the primate SN compared to other serotypes [249, 250]. Second, 
AAV vectors support long-lasting transgene expression with even a single delivery [249]. Third, 
AAV vectors show no pathogenicity and have been used to safely deliver genetic material in 
clinical trials of neurturin and human aromatic L-amino acid decarboxylase (hAADC) [187, 189, 
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251]. Finally, Dr. Robert Burke, with whom we collaborated to perform these in vivo 
experiments, has extensive experience in utilizing AAV1 to deliver myristoylated Akt or 
constitutively-active Rheb to the SNpc of mouse models, often in the context of Parkinson’s 
disease [138-140, 142, 174, 252, 253]. 
Our choice of TMP dosing and treatment paradigm was based on previously published 
literature utilizing the DHFR-derived DD system with TMP to inducibly express various proteins 
(YFP, GDNF) in the rat striatum. In all cases, TMP was administered orally, within the drinking 
water of the animals, for a 3-week period before beginning experimental procedures [191, 211, 
212]. Additionally, these groups demonstrated successful induction of DD-fusion proteins within 
the rat striatum with TMP doses ranging from 0.1-0.5 mg/ml. We chose a 1.0 mg/ml dose of 
TMP that exceeded the doses used by these groups to better ensure that TMP would be present in 
high enough concentrations to regulate DD-Akt(E40K), as supported by the literature. 
  In this chapter, we investigate the inducibility and behavior of DD-Akt(E40K) in vivo 
within the mouse SNpc. With the supporting literature of DHFR-derived DD systems within 
rodent brains, we anticipated that oral TMP administration would induce expression of DD-
Akt(E40K) within the mouse SNpc. Furthermore, we anticipated similar physiological effects to 
that observed with overexpression of myristoylated-Akt, including trophic effects on cell size 
and protection of dopaminergic neurons and axonal projections against PD mimetic toxin insults 
[138]. The findings presented here demonstrate a surprising lack of DD-Akt(E40K) inducibility 
in the SNpc, but significant TMP-mediated induction within the striatum, suggesting regional 
variability of the DD system efficacy. Additionally, our data corroborate reported trophic effects 




5.2:  Results 
 Validating DD-Akt(E40K)-Flag In Vitro 
 The construct we created for packaging into an AAV vector was additionally Flag-tagged 
at the 3’ end of the expression construct to allow for easy detection of the fusion protein if 
expressed within the SNpc of mice. Although DD-Akt(E40K) already contained an HA tag, the 
protocol for detecting Flag through immunohistochemistry had previously been validated and 
established by our collaborator, Dr. Robert Burke [138]. Thus, we chose to utilize a Flag-tagged 
version of DD-Akt(E40K) for our in vivo experiments.  
 To verify that the addition of the Flag tag does not interfere with the inducibility of DD-
Akt(E40K), we tested the TMP-mediated induction of Flag-tagged DD-Akt(E40K), denoted as 
“DD-Akt(E40K)-Flag”, along with non-Flag-tagged DD-Akt(E40K) in vitro in HEK293 cells. 
The two constructs were tested concurrently following the same experimental protocol as 
described for induction experiments in Chapter 3. Briefly, HEK293 cells were transiently 
transfected and treated with 10 µM TMP for 24 hours before isolating protein samples for 
immunoblotting. Samples were analyzed for pAkt473 expression, normalized to ERK for 
loading, and compared across conditions to identify any potential differences in induction with 
the addition of a C-terminal Flag tag (Figure 5.1). The results indicate no statistically significant 
difference with Flag addition in the basal levels of DD-Akt(E40K) when untreated with TMP or 
induced levels when treated with TMP. This finding thus demonstrates that the addition of a Flag 






 Measuring DD-Akt(E40K)-Flag Induction In Vivo 
Once we validated that the addition of the Flag tag at the C-terminus of DD-Akt(E40K) 
did not affect its inducibility, we wanted to determine whether DD-Akt(E40K)-Flag can be 
controlled in the mouse SNpc by oral TMP administration.  
Because the treatment protocol requires TMP to be delivered through the drinking water 
 
Figure 5.1: Addition of Flag tag does not affect inducibility of DD-Akt(E40K) 
DD-Akt(E40K) with only an HA tag (as used in all in vitro experiments) and with an 
additional Flag tag at the 3’ end of the expression construct was cloned into a pBL vector. 
Constructs were transiently transfected into HEK293 cells and treated with 10 µM TMP for 
24 hours. Protein samples were processed for immunoblotting and levels of pAkt473 were 
quantified, normalized to ERK for loading, and normalized to levels in cells transfected 
with the HA only-tagged DD-Akt(E40K) – TMP. Graph shows means with SEM. N=3 
independent experiments, each with 2-3 replicates per condition. N.s. vs HA only-tagged 
DD-Akt(E40K) – TMP determined by 2-way ANOVA with multiple comparisons. 
pAkt473
ERK
- TMP + TMP
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of mice, solubility in water was an important criterion for the antibiotic. However, the TMP 
compound used in our in vitro studies has low solubility in water. Therefore, we chose to use a 
TMP-lactate salt form of the antibiotic (purchased from ChemImpex International, Inc, catalog # 
CI-03552-5G), which is soluble in water up to 20 mg/ml. Before beginning the in vivo studies, 
we aimed to verify that TMP-lactate works as intended and induces DD-Akt(E40K) as TMP 
does. To test this compound, HEK293 cells were transiently transfected DD-Akt(E40K) and 
treated with either TMP or TMP-lactate, both at an equivalent dose of 10 µM TMP, for 24 hours. 
When levels of pAkt473 were quantified, the data showed that TMP-lactate was able to induce 
DD-Akt(E40K) to comparable levels as TMP used in previous in vitro studies as described in 
Chapter 3 and 4 (Figure 5.2).  
 
 
Figure 5.2: TMP-lactate induces DD-Akt(E40K) 
HEK293 cells were transfected with DD-Akt(E40K) and treated with 10 µM TMP or 
TMP-lactate for 24 hours. Protein samples were collected for immunoblot analysis and 
quantified for pAkt473, normalized to ERK for loading. Graph shows means with SEM, 
N=2 samples per condition. N.s. determined by 2-way ANOVA. 
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Once TMP-lactate was verified to work in an equivalent manner to TMP, we sought to 
test the construct in vivo, in the SNpc of mice. To do this, AAV1-DD-Akt(E40K)-Flag was 
delivered unilaterally to the substantia nigra of adult (8 week) male C57BL/6 mice. TMP 
treatment began at 3 weeks post-injection to allow for expression of the transgene delivered by 
AAV. The injected mice were given 1 mg/ml TMP in the drinking water, or maintained on 
untreated water as a control, for 3 weeks and then processed for staining of Flag-tagged proteins 
(Figure 5.3). As mentioned in Section 5.1, the length and dosing of TMP was based previous 
literature describing the control of DD-fusion proteins in the striatum of rats using a dose range 




Nigral sections of injected mice were stained for Flag expression as a direct readout of 
DD-Akt(E40K)-Flag expression. A complete set of serial sections was cut through the substantia 
nigra and every fourth section was processed for staining of Flag. Stained sections were 
subsequently analyzed stereologically in a blinded manner to determine the number of total Flag-
positive neurons within the SNpc as a measure of DD-Akt(E40K)-Flag expression. Surprisingly, 
there was no visibly observable difference in numbers of Flag-stained neurons or intensity of 
staining in the substantia nigra of mice with or without TMP treatment through visible 
 
 
Figure 5.3: Treatment timeline for in vivo induction experiments 
Weeks 0 1 2 3 4 5 6













observation (Figure 5.4). However, though visible observation, we suspected that there might be 
a distinction in localization of staining between the treatment groups. Thus, we quantified the 
number of SNpc neurons with nuclear, cytoplasmic, or both nuclear and cytoplasmic localization 
of Flag staining as a readout of DD-Akt(E40K)-Flag induction using stereological methods (see 
Figure 5.4 for examples of each). Counts were done in a blinded manner, such that the treatment 
group of the mouse was not known until after counts had been completed.  
When the nigral sections were quantified in this manner, there was no statistically 
significant difference in the quantity of Flag-positive neurons between the treatment groups, 
regardless of staining localization (Figure 5.5). As a result, when total counts were compiled, 
there was again no statistically significant difference in number of Flag-positive neurons between 
treatment groups (Figure 5.6). These results indicate that DD-Akt(E40K)-Flag is not controllable 






Figure 5.4: DD-Akt(E40K)-Flag is expressed in SNpc of mice 
Adult C57BL/6 mice were treated with a unilateral AAV-DD-Akt(E40K)-Flag injection into 
the SNpc. At 3 weeks post-viral injection, mice were treated with 1 mg/ml TMP in their 
drinking water for 3 weeks and processed for staining of Flag. Representative images of Flag 
stained neurons in the SNpc of both non TMP-treated and TMP-treated mice are shown 
above. Red arrows indicate examples of cytoplasmic staining; red arrowheads indicate 






This unexpected result contrasted with previous published studies demonstrating efficient 
control of the DD fusion protein in rodent brain by oral TMP administration [191, 211-213]. 
However, all of these studies involved expression of a DD fusion protein within the striatum 
rather than the substantia nigra, thus introducing the possibility of a region-dependent effect on 
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Figure 5.5: Flag-positive neurons in the 
SNpc of non TMP-treated and TMP-
treated mice 
AAV-DD-Akt(E40K)-Flag injected mice 
were divided into control and experimental 
groups, with the control group being given 
normal drinking water and the experimental 
group being given TMP-treated drinking 
water for 3 weeks. The SNpc was then 
sectioned and processed for stereological 
quantification of Flag-stained neurons, 
categorizing staining pattern by nuclear, 
cytoplasmic, or both. Graph is mean with 
SEM. N=7 mice for -TMP, N=6 mice for 
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Figure 5.6: DD-Akt(E40K)-Flag 
shows no induction by TMP in the 
SNpc of mice 
AAV-DD-Akt(E40K)-Flag injected 
mice were divided into control and 
experimental groups, with the control 
group being given normal drinking 
water and the experimental group 
being given TMP-treated drinking 
water for 3 weeks. The SNpc was then 
sectioned and processed for 
stereological quantification of Flag-
stained neurons. The data represents 
total Flag-positive neurons in the SNpc 
per mouse. Graph is mean with SEM. 
N=7 mice for -TMP, N=6 mice for 




we performed unilateral injections of AAV1-DD-Akt(E40K)-Flag into the striatum of adult (8 
week) male C57BL/6 mice, following the same TMP treatment protocol of 1 mg/ml administered 
in the drinking water for 3 weeks (Figure 5.3). After 3 weeks of TMP-supplemented water, or 
non-treated water for the control group, the striatum was processed for Flag staining by 
collecting a complete set of serial sections and staining every sixth section for Flag.  
Interestingly, the striatal sections of these mice appeared to have differences in Flag 
staining pattern that correlated with TMP treatment (Figure 5.7). Although both treatment groups 
exhibited Flag-positive neurons, indicating that DD-Akt(E40K)-Flag was expressed, the staining 
in non TMP-treated mice appeared to be limited to the needle tract and along the external capsule 
of the striatum. In contrast, Flag staining in TMP-treated mice appeared to be more diffuse along 
the needle tract in all mice and show a distinct area of staining in the medial striatum in four out 
of seven mice, neither of which was present in non TMP-treated mice (Figure 5.7). The peculiar 
staining pattern closer to the external capsule may be a result of viral diffusion through less 
dense tissue along the white matter fiber tracts. The staining within the medial striatum that only 
appears with TMP treatment may be a reflection of a lower concentration of virus farther away 
from the injection site, leading to less intense expression of DD-Akt(E40K)-Flag and decreased 





To determine the number of total Flag-positive neurons within the striatum. A complete 
set of serial sections was cut through the striatum and processed for Flag staining at every sixth 
section. These sections were subsequently analyzed stereologically in a blinded manner to 
determine the number of total Flag-positive cells within the striatum across non-TMP treated and 
TMP treated groups (Figure 5.8). We found a statistically significant difference between 
treatment groups with non-TMP treated mice exhibiting an average of 13,238 ± 2602 Flag-
stained neurons and TMP-treated mice exhibiting an average of 24,009 ± 2984 Flag-stained 
neurons (*p = 0.03, Figure 5.8), indicating that DD-Akt(E40K)-Flag is controllable by oral TMP 
administration in the striatum of mice. The average induction of DD-Akt(E40K)-Flag, as 
measured by the proportional increase in number of Flag-stained neurons in TMP-treated mice 
compared to non TMP-treated mice, was 80%, or 1.8-fold. These results suggest a number of 
important points: 1) Oral TMP administration, as used in our protocol, is capable of inducing 
DD-Akt(E40K)-Flag, as has been demonstrated by other groups using other DD-fusion proteins, 
2) There is a region-specific sensitivity in the inducibility of DD-Akt(E40K)-Flag, as indicated 
  
- TMP + TMP
Figure 5.7: DD-Akt(E40K)-Flag staining 
in the striatum of mice 
Adult C57BL/6 mice were treated with a 
unilateral AAV-DD-Akt(E40K)-Flag 
injection into the striatum. At 3 weeks post-
viral injection, mice were treated with 1 
mg/ml TMP in their drinking water for 3 
weeks and processed for staining of Flag. 
Representative images of Flag staining in the 
striatum of both non TMP-treated and TMP-
treated mice are shown to the left. Red 
arrows indicate staining in the medial 
striatum; black arrowheads indicate external 
capsule staining; black arrows indicate 
staining proximal to the needle track. 
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by the contrasting results from DD-Akt(E40K)-Flag induction in the SNpc compared to the 
striatum, 3) The efficient control of DD-Akt(E40K)-Flag in the SNpc is lacking either due to 
high background expression off TMP treatment, small induction of stability with TMP treatment, 





 DD-Akt(E40K)-Flag has Trophic Effects In Vivo 
 Previous work from the Burke laboratory has demonstrated a clear trophic effect of 
virally expressed myristoylated Akt on neurons of the SNpc [138]. This is in accordance with 
 
Figure 5.8: DD-Akt(E40K)-Flag is induced by TMP treatment in the striatum of mice 
AAV-DD-Akt(E40K)-Flag was injected unilaterally into the striatum of adult C57BL/6 
mice and given non-treated water or 1 mg/ml TMP-treated water for 3 weeks. Every 
sixth section of a complete set were stained for Flag and analyzed stereologically to 
determine the total number of Flag-stained cells within the whole striatum per mouse. 
Graph shows means with SEM. N=5 mice for –TMP, N=8 mice for +TMP. *p = 0.03, 
unpaired t-test. 
Mean 13,238 24,009 Induction
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reported downstream functions of Akt signaling mediating cellular growth [117]. However, the 
constitutively active Akt(E40K) mutant has not previously been studied for neurotrophic effects 
in vivo. Demonstration of this would serve three main purposes: 1) Validation of the mutant 
Akt(E40K) to mimic known downstream physiological effects of Akt signaling in vivo in a 
neuronal context, 2) Proof of principle to show that DD-Akt(E40K)-Flag retains the ability to 
activate signaling pathways in vivo that lead to known Akt cellular effects, and 3) Additional 
evidence that DD-Akt(E40K)-Flag is not inducible by TMP treatment in the SNpc of mice. 
Here, we have unilaterally delivered Akt(E40K)-Flag to the SNpc of adult (8 week) 
C57BL/6 mice using AAV1. At 10 weeks post-injection, the SNpc were processed for TH 
expression to identify dopaminergic neurons and determine the trophic effects, if any, of 
Akt(E40K) signaling on dopaminergic neurons in the SNpc. Through visible observation, a clear 
and observable increase in average dopaminergic neuronal body size, as measured by area, was 
seen in addition to a thickening of neurites and increase in density of TH-stained neuropil 
surrounding the SNpc neurons (Figure 5.9).  
The average cell body size was quantified for both control (non-injected) and 
experimental (injected with AAV1-Akt(E40K)) hemispheres, through a systematic method to 
randomly choose stained neurons within the region of interest across representative caudal, 
medial, and rostral sections of the SNpc. When the neuronal cell size was quantified as such, the 
average area of the neuronal cell body within the injected SNpc was found to be greater than 2-
fold that of the control side, with the average area in the Akt(E40K)-injected hemisphere being 
411 ± 13 µm2 and the average area in the control hemisphere being 201 ± 5 µm2 (Figure 5.10). 
This difference in neuronal cell size was found to be statistically significant (p ≤ 0.0001, 
unpaired t-test).  
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The data also demonstrates a clear difference between neuronal cell sizes of the 
Akt(E40K) injected and uninjected hemispheres when presented as a frequency distribution of all 
measured neurons based on size (Figure 5.11). We see a clear shift in the distribution of 
dopaminergic neuronal cell body areas to the right when injected with AAV-Akt(E40K)-Flag, 
with the smallest measured TH-positive neuron from the injected hemisphere having an area 
approximately 11% larger than the smallest measured TH-positive neuron from the non-injected 
hemisphere. These results clearly demonstrate that Akt(E40K) is capable of inducing a trophic 
effect on neuron size within the SNpc, as would be expected from reported functions of Akt and 









Figure 5.9: Akt(E40K) has trophic effects on TH+ neurons in the SNpc 
AAV-Akt(E40K)-Flag with no DD domain was unilaterally injected into the SNpc of mice 



















Figure 5.10: Akt(E40K) doubles the 
average cell size of TH+ neurons in the 
SNpc 
The average cell body area of randomly 
chosen TH+ neurons in caudal, medial, 
and rostral sections of the SNpc was 
measured through the StereoInvestigator 
program. The contralateral, uninjected 
hemisphere was used as controls. The 
average increase in cell size was found to 
be 2-fold with injection of AAV-
Akt(E40K), (****p < 0.0001, unpaired t-
test). Graph is mean with SEM. N=105 






The next question became whether DD-Akt(E40K)-Flag can exhibit a similar 
physiological effect. Our previous results had demonstrated that the protein was expressed at 
quantities large enough for clear detection by Flag staining, although expression levels were not 
detectably controlled by TMP administration. We therefore measured the cell size of neurons 
within the SNpc of mice that were unilaterally injected with AAV1-DD-Akt(E40K)-Flag and 
either given normal or TMP-treated water for 3 weeks (Figure 5.12). The average TH+ neuron 
cell size on the uninjected hemisphere was measured at 189.7 ± 4.8 µm2 (-TMP) and 182.1 ± 4.2 
µm2 (+TMP), while on the injected hemisphere was measured at 232.2 ± 4.8 µm2 (-TMP) and 
227.0 ± 5.2 µm2 (+TMP). Thus, we found that there was a significant increase in average TH+ 
neuron cell size by 23-25% with DD-Akt(E40K)-Flag injections compared to neurons of the 
uninjected hemisphere (p < 0.0001 vs. -AAV-DD-Akt(E40K)-Flag, 2-way ANOVA). In 
concordance with our results showing no apparent induction with TMP treatment, there was also 
 
Figure 5.11: Akt(E40K) expression increases dopaminergic neuron cell size 
The frequency distribution of all TH+ neuronal cell body areas demonstrates a clear trophic 
effect of Akt(E40K) expression on TH+ neurons in the SNpc.  
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no difference found in cell size that correlated with TMP treatment (Figure 5.12, 2-way 
ANOVA).  
Furthermore, the frequency distribution of all neuronal cell area measurements clearly 
show a shift upward in the range of neuron sizes in the hemisphere injected with the DD-
Akt(E40K)-Flag compared to measurements from the uninjected hemisphere (Figure 5.13). 
These results reveal that DD-Akt(E40K)-Flag retains its trophic effect on neurons of the SNpc, 
even with the addition of the DD domain. However, the issue remains that the degradation of the 
protein within the SNpc is not controllable by orally administered TMP, in contrast to published 
results by other groups.  
Further, it is interesting to note that the magnitude of the trophic effect found with 
expression of DD-Akt(E40K)-Flag was less than that of Akt(E40K). However, we cannot be sure 
that the expression levels of DD-Akt(E40K)-Flag and Akt(E40K) are equal. The two 
experiments were assessed for trophic effects at different lengths of time after injection (6 weeks 
for DD-Akt(E40K)-Flag and 10 weeks for Akt(E40K)). Additionally, the viral titer of DD-
Akt(E40K)-Flag was 2.3 x 1011 viral molecules/ml compared to the viral titer of Akt(E40K) at 
4.9 x 1012 viral molecules/ml. Although both of these differences could lead to the distinct results 
in trophic effect observed, it is worth nothing that the expression construct was identical with 
regards to the backbone plasmid and promoter. Given the drastic increase in average neuronal 
cell size by Akt(E40K) at 104% increase compared to an increase of 23-25% by DD-Akt(E40K)-
Flag, the question remains whether the additional 4 weeks of time after injection and higher viral 








Figure 5.12: DD-Akt(E40K)-Flag has trophic effects on dopaminergic neurons of the SNpc 
AAV-DD-Akt(E40K)-Flag was unilaterally injected into the SNpc of mice and processed 6 
weeks post-injection for Flag expression. The average cell body area of randomly chosen 
Flag+ neurons in caudal, medial, and rostral sections of the SNpc in both non TMP-treated 
and TMP-treated mice was measured through the StereoInvestigator program. Neurons of the 
contralateral (uninjected) hemisphere was used as controls. Graph shows means with SEM. 
****p < 0.0001; n.s. as determined by 2-way ANOVA with multiple comparisons. N=175 
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Figure 5.13: DD-Akt(E40K)-Flag induces overall increases in dopaminergic neuron cell 
size 
The frequency distribution of all TH+ neuronal cell body areas demonstrates a clear trophic 
effect of DD-Akt(E40K)-Flag expression on TH+ neurons in the SNpc of (A) TMP-treated 
mice, N=175 neurons from 7 mice, and (B) non TMP-treated mice, N=150 neurons from 6 
mice. 
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5.3:  Discussion 
 In Chapter 5, we explored the feasibility of the DD-Akt(E40K) system as a Parkinson’s 
disease therapy for clinical use by investigating its effects in an in vivo mouse model. Although 
previous studies in the literature had demonstrated robust induction of the DD system when 
fused to YFP, GDNF, and GTP cyclohydrolase 1 (GCH1) in rodent models with the oral 
administration of TMP [191, 211-213], we were not able to find any sign of induction of DD-
Akt(E40K)-Flag with TMP treatment in the SNpc of mice. Interestingly, there was a detectable 
and statistically significant induction of DD-Akt(E40K)-Flag with TMP treatment that was 
observed in the striatum of mice, suggesting a regional difference in sensitivity of the DD system 
to TMP-mediated stabilization and induction. Additionally, significant physiological effects on 
the average size of the cell body were observed with the expression of DD-Akt(E40K)-Flag on 
the neurons of the SNpc. This trophic effect is in concordance with reported effects of Akt 
signaling on cell growth through mTORC1 [117].  
The lack of TMP-mediated control over DD-Akt(E40K)-Flag in the SNpc is in contrast to 
previous published studies on the DHFR-derived DD system in the CNS of rodent models, which 
have demonstrated both clear induction of DD fusion proteins with YFP, GDNF, and GCH1 in 
the striatum as well as low baseline level expression[191, 211-213]. This could be due to a 
number of reasons, such as the potential inadequate sensitivity of our quantification method, the 
use of a different viral vector, differences in the protein of interest that is fused to the DD 
domain, issues with TMP administration (i.e. insufficient TMP reaching the region of 
expression), or regional differences that affect DD system behavior, all of which are explored 
below. 
It is possible that our method of using the quantity of Flag-stained neurons as a readout of 
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DD-Akt(E40K)-Flag induction is not sensitive enough to detect 2.5 to 5-fold increases, as 
expected from our in vitro studies described in Chapter 3. Due to the nature of the enzymatic 
reaction used for immunohistochemical detection of Flag, it is difficult to ascertain the levels of 
Flag-tagged protein by intensity of staining. However, the successful detection of DD-
Akt(E40K)-Flag induction in the striatum indicates that the quantification of Flag-stained 
neurons is an effective method to detect induction of DD-Akt(E40K)-Flag. Thus, the detection 
method is unlikely to account for the contrasting results of our studies from published data. 
Viral vectors have a variety of unique characteristics, such as efficiency and specificity of 
infection, that may lead to differences in expression and potentially the behavior of a transgene 
[254]. As such, we considered the possibility that our use of an AAV vector may account for the 
contrasting results found with TMP-mediated inducibility of DD-Akt(E40K)-Flag. Within the 
literature, we found that most of the published studies of DHFR-derived DD have utilized 
lentiviral vectors to deliver their protein of interest to the striatum of rodents [191, 211, 212]. 
However, the most recent study in 2015 from the laboratory of Deniz Kirik utilized an AAV 
vector of serotype 5 with ITR sequences from serotype 2 (AAV2/5) [213]. This group 
demonstrated that delivery of DD-GCH1 using an AAV vector can lead to successful expression 
of DD fusion protein in the rodent CNS. Furthermore, their findings indicate that DD-GCH1 
protein levels were regulatable by orally-administered TMP. There remains the important 
distinction between the AAV serotype used in their study (AAV2/5) and ours (AAV1). However, 
the AAV1 serotype used for our study has been validated by our collaborator Dr. Robert Burke’s 
laboratory to efficiently induce expression of transgenes in mouse CNS [138, 140, 142, 174, 
252]. Thus, we believe that the lack of TMP control over DD-Akt(E40K)-Flag is not likely due 
to differences in viral vector used.  
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There remains the possibility that the fusion of Akt to DD renders the system less 
efficient with regards to its regulation by TMP. Akt is by far the largest protein to be fused to DD 
and expressed in the CNS, with Akt having a molecular weight of approximately 60kDa 
compared to GCH1 at 28kDa, GDNF at 30kDa, and YFP at 26 kDa. The significantly larger size 
of the protein could potentially interfere with the DD domain’s propensity to misfold and confer 
destabilizing function, contributing to the basal levels of DD-Akt(E40K)-Flag that we observe 
without TMP. However, the in vitro studies described in Chapters 3 and 4 exhibit robust 
induction of DD-Akt(E40K)-Flag, with an observable induction of protective effects against 6-
OHDA and MPP+ when treated with TMP and no protection found without TMP treatment, 
demonstrating that the DD-Akt fusion protein can be regulated by TMP within physiologically 
relevant levels in cell culture and have minimal basal levels. There also remains the possibility 
that the addition of a Flag tag to the C-terminus of DD-Akt(E40K) may affect its inducibility in 
vivo. However, we have demonstrated that at least in culture conditions, the additional Flag tag 
does not affect TMP-mediated induction (Figure 5.1). Thus, we believe it is likely that there is 
more at play than the difference in the protein that is fused to DD. It may be that the DD system 
behaves differently in culture compared to the full organismal level for reasons that may merit 
further exploration. 
With regards to TMP administration being a potential contributor to the contrasting 
results from our studies with DD-Akt(E40K)-Flag inducibility in the SNpc, there are distinctions 
to the TMP treatment paradigm as well as the source of TMP used. However, we believe it is 
unlikely that these differences are enough to explain the lack of inducibility that we observe with 
DD-Akt(E40K)-Flag in the SNpc. The dosing of TMP in the drinking water of the animals in our 
studies was 1.0 mg/ml, 2 to 10-fold higher than published studies of DD-YFP and DD-GDNF in 
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the rodent striatum [191, 211, 212]. The most recent study by Deniz Kirik, published after we 
began our in vivo studies, utilizes a dose-escalation design with 3 doses beginning at 0.5 mg/ml 
and ending at 2.0 mg/ml, with 6 weeks spent at each dose. However, their motor behavioral 
assessment of the mice did not show significant differences between the middle dose of 1.0 
mg/ml and ending dose of 2.0 mg/ml, suggesting that our TMP dose of 1.0 mg/ml should be 
sufficient to induce stabilization of DD-Akt(E40K)-Flag over untreated animals. Furthermore, 
the Kirik study demonstrated minimal basal expression of DD-GCH1 in untreated animals as 
detected by immunohistochemistry, thus suggesting that any difference in TMP treatment 
protocol would not explain the basal expression of DD-Akt(E40K)-Flag that we observe in our 
study. It is possible that our shorter length of TMP treatment time at 3 weeks compared to the 
full 18 weeks in the Kirik study could contribute to the lack of regulatory effect we observe with 
DD-Akt(E40K)-Flag in the SNpc. However, this 3-week treatment period has been demonstrated 
to efficiently induce stabilization and accumulation of DD fusion proteins in the earlier DHFR-
derived DD studies [191, 211, 212]. Additionally, the TMP used in our in vivo studies was 
obtained from a different source as a TMP-lactate salt from ChemImpex International, Inc, 
whereas the other studies utilized an oral TMP suspension obtained from Meda AB, Solna, 
Sweden [191, 211-213]. However, based on our experimental verification of TMP-lactate in 
culture (Figure 5.3), it is unlikely that this would be a factor affecting inducibility of DD-
Akt(E40K)-Flag in our hands. Thus, differences in our TMP treatment paradigm and source are 
unlikely to explain our conflicting results from previously published data. 
Finally, we considered the possibility of a regional difference as an explanation for these 
contrasting data of TMP-mediated regulation of the DHFR-derived DD system. Among the 
above reasons explored, this region-specific sensitivity appears to be the most supported by our 
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data thus far. Our results showing induction with TMP in the striatum but not in the SNpc 
suggest that there is a region-specific effect that affects the sensitivity of DD system regulation 
by TMP such that there is detectable inducibility in the striatum but not the SNpc.  
There are two possible general factors contributing to the observed lack of control over 
DD-Akt(E40K)-Flag protein with TMP in the SNpc: 1) high basal levels caused by inefficient 
degradation without TMP treatment, or 2) low stabilization levels with TMP administration as 
measured by a lack of increase in detectable DD fusion protein levels in TMP-treated groups. 
The results of the work described in this chapter suggest some combination of the two in the case 
of DD-Akt(E40K)-Flag in the SNpc, with three key supporting lines of evidence:  
1) The detection of Flag staining in non TMP-treated animals reveals the sufficient 
presence of DD-Akt(E40K)-Flag protein even in the absence of the stabilizing ligand, 
supporting that high basal levels are a factor in the lack of detectable induction with 
TMP treatment,  
2) The smaller magnitude of trophic effect by DD-Akt(E40K)-Flag at 23-25% increase 
in average cell size compared to myristoylated Akt at 50% increase [138] or 
Akt(E40K) at a little over 100% increase, supporting that increase of stabilization is 
insufficiently achieved with TMP compared to its fully activated potential, and 
3) The lack of increase in trophic effect observed with TMP treatment for 3 weeks 
compared to untreated animals, thus suggesting that the TMP was not able to stabilize 
DD-Akt(E40K)-Flag above its baseline levels. 
There are a few potential mechanisms through which regional differences could affect the 
DD system. First, the overall volume of the striatum is much larger than the SNpc, thus 
implicating the possibility that the concentration of virus on a per cell basis is higher in the SNpc 
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than in the striatum. This may contribute to higher basal expression levels of the transgene in the 
SNpc compared to the striatum. However, this mechanism assumes that the diffusion of viral 
particles during injection is confined to the target region, for which there is no supporting 
evidence to our knowledge. Furthermore, the extracellular space through which viral particles 
would diffuse has been estimated to be approximately 50% larger in the SN than in the striatum 
[255], suggesting that the overall concentration of viral particles after injection may actually be 
lower in the SNpc than in the striatum.   
Second, there may be regional differences in the pharmacokinetics of TMP such that the 
TMP concentration in the striatum exceeds that in the SNpc. Our data presented in Chapter 3 
established that TMP-mediated stabilization of DD-Akt(E40K) is dose-responsive, which implies 
that regional differences in TMP concentration within the CNS would directly lead to differences 
in stabilization and therefore accumulation of DD-Akt(E40K). Pharmacokinetics of drug target 
site distribution within the CNS depends on a large variety of factors, including drug transport 
across the blood-brain barrier, local metabolism, and regional tissue permeability, all of which 
may exhibit regional distinctions between the striatum and SNpc [256]. A recent study in 2016 
assessing the regional distribution of antipsychotic drugs in rats found evidence of significant 
differences in region-specific blood-brain barrier penetration as well as intra-brain distribution 
and tissue binding [257]. The study further demonstrated evidence of the striatum as a brain 
region with one of the highest blood-brain barrier penetration. To test whether regional 
differences in TMP access might account for the contrasting inducibility in the striatum 
compared to the SNpc, we attempted to test inducibility of DD-YFP, as a positive control, within 
both of these brain regions. Unfortunately, we observed severe transduction toxicity with AAV-
delivered DD-YFP, making our experiment inconclusive (data not shown). Thus, there remains 
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the possibility that regional TMP concentration differences may play a role in the regional 
inducibility of DD-Akt(E40K). 
The last but perhaps most intriguing possibility is that the SNpc may be much poorer in 
protein degradation than the striatum, which could be related to selective vulnerability in 
Parkinson’s disease [237, 238]. With the putative mechanism of DD-mediated destabilization 
being dependent on the ubiquitin-proteasome system (UPS) [214], a difference in proteasomal 
degradation efficiency between dopaminergic neurons of the SNpc and GABAergic neurons of 
the striatum could thus explain the insufficient degradation of the DD-Akt(E40K)-Flag in the 
SNpc, even in untreated animals. This mechanism is supported by our data presented in Chapter 
3, demonstrating a greater than 250% increase in basal levels of DD-Akt(E40K) in dopaminergic 
neurons compared to neighboring non-dopaminergic cells in vitro (Figure 3.12). Additionally, 
there is much evidence supporting dysfunction of the UPS in Parkinson’s disease [235, 236], and 
there have also been reports of decreased levels of proteasome activators, PA28 and PA700, in 
the SNpc compared to the striatum and cortex [237]. Furthermore, a study assessing the three 
catalytic activities (chymotrypsin-like, trypsin-like, and trypsin- and peptidylglutamyl-peptide 
hydrolase (PGPH)-like) of the proteasome across different species and brain regions revealed 
that two out of the three catalytic activities were significantly reduced in the striatum but only in 
the SN were all three catalytic activities significantly reduced [238]. Thus, the unexpected result 
of DD-Akt(E40K)-Flag inducibility in the striatum but not the SNpc may be due regionally 
reduced UPS activity, contributing to high basal levels of the protein off-TMP in the SNpc. 
Another interesting result from the data presented in this chapter is the finding that the 
trophic effect of Akt(E40K) exceeded the reported effect of myristoylated Akt (myr-Akt) by 
approximately 2-fold, with Akt(E40K) having a 100% increase in average cell size compared to 
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the 50% increase found with myr-Akt expression [138]. This difference in the magnitude of 
effect contrasts with literature that suggests higher activity levels of myr-Akt than that of PH 
domain mutants, as is implied by much larger increases in heart size with overexpression of myr-
Akt compared to Akt(E40K) in rats [232, 233]. Additionally, both myr-Akt and Akt(E40K) 
increased average cell size by a much larger proportion compared to that caused by DD-
Akt(E40K). As discussed above, the length of time after viral injection that the animals were 
processed was distinct in each case; DD-Akt(E40K)-Flag injected mice were processed 6 weeks 
post-injection, myr-Akt injected mice were processed 7 weeks post-injection [138], and 
Akt(E40K) injected mice were processed 10 weeks post-injection. Thus, the increase in 
magnitude of trophic effect could potentially be explained by the differences in time that the 
active Akt was expressed in the brain before processing. Perhaps an even more convincing 
reason for the contrasting results lies in the viral titers – the titer of AAV-DD-Akt(40K)-Flag 
was estimated to be approximately 20-fold lower than the titer of AAV-Akt(E40K). Regardless, 
these contrasting results suggest that the trophic effect of DD-Akt(E40K)-Flag did not reach its 
maximum potential as suggested by the drastic increases in cell size with expression of myr-Akt 
and Akt(E40K).  
The in vivo studies presented in this chapter reveal a number of important considerations. 
First, the utility of the DD system currently as a tool to control protein levels is limited in a 
clinical setting due to its variability of inducibility that may be affected by the region of 
expression. Second, this same variability of inducibility provides the possibility of further control 
over the levels of transgene or protein in gene therapy. If the reasons behind this variability are 
explored further, they could provide insights into very relevant considerations for any future 
therapies that aim to control levels of protein level, as well as alternative methods of fine tune 
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control in gene therapy in the CNS. Third, this study reemphasizes the physiological potential of 
Akt signaling that, if harnessed properly, presents a viable target to control cell growth and 




Chapter 6: Conclusions and Future Directions 
This dissertation explores the applicability of a unique protein stabilization technique as a 
gene therapy tool in Parkinson’s disease. This chapter will summarize the major achievements 
and future directions of this project. 
 
6.1:  Strategy for Control of Akt Signaling In Vitro 
 Here we have reported the development of a unique method for controlling Akt signaling 
in vitro. The use of DHFR-derived destabilizing domains (DD) for post-transcriptional control of 
protein levels by controlling protein stability was first reported by the Wandless group of 
Stanford University in 2010. Since then, the original publication has been cited 71 times by 
various groups utilizing the technique for control of diverse proteins as well as potential pairing 
with other innovative technologies, such as CRISPR/Cas9, for wider applications [191, 205, 211-
213, 258-260].  
 We have applied this strategy to create a tool for the control of active Akt levels through 
the fusion of a DD domain to the N-terminus of Akt(E40K). This strategy employs the 
inexpensive, non-toxic, and commonly used antibiotic, Trimethoprim (TMP), to increase the 
levels of phosphorylated Akt kinase in a dose-responsive and reversible manner (Chapter 3.2.1 
and Chapter 3.2.3). Furthermore, the full induction of active Akt with TMP treatment is 
achievable within 24 hours (Chapter 3.2.3). Importantly, we have presented evidence for the 
presence of DD-Akt(E40K) kinase activity through observations of increased phosphorylated 
FoxO4, a known Akt substrate, with TMP-mediated induction (Chapter 4.2.1).  
 As we have demonstrated the successful inducibility of this activateable Akt within 
multiple cellular contexts (human embryonic kidney cells, PC12 cells, rat cortical neurons, rat 
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dopaminergic neurons), this unlocks the possibility of utilizing this system in a variety of cellular 
studies regarding Akt signaling. Furthermore, if used in conjunction with gene editing 
technologies including CRISPR/Cas9, this tool could potentially be used to permit control of 
endogenous Akt signaling levels through an external ligand, TMP. Further studies could utilize 
this inducible Akt as a tool to potentially study unanswered questions about Akt signaling such 
as the timing of Akt downstream signaling events, the reliability of certain downstream events on 
the dose or level of active Akt, the distinctions of Akt signaling via recruitment to the plasma 
membrane compared to recruitment to other intracellular membrane structures, and the nuances 
of Akt regulation and feedback inhibition. 
 However, this strategy is not without limitations. As seen in our findings presented in 
Chapter 3, there exists a certain level of active Akt even in the absence of the stabilizing ligand. 
This is likely to always be the case due to the post-translational nature of the technology in 
which the protein is constantly expressed but tagged for proteasomal degradation. Although our 
data presented in Chapter 3 and Chapter 4 suggest that this basal level of DD-Akt(E40K) is not 
sufficient to induce detectable changes downstream in phosphorylation of FoxO4 or 
physiological pro-survival activity, there may exist certain cellular contexts in which the 
dependence of DD-Akt(E40K) inducibility on endogenous protein degradation systems is 
prohibitive. This last point is supported by our detection of higher basal DD-Akt(E40K) levels in 
dopaminergic neurons of the rat midbrain than non-dopaminergic neurons within the same 
cultures (Chapter 3.2.1), as well as our in vivo data demonstrating lack of detectable induction in 
the SNpc of mice, an area which has been suggested to have lower proteasomal activity (Chapter 
5.2.2) [237, 238]. Further studies could directly assess basal proteasomal activities of different 
cellular contexts utilizing the basal activity levels of DD-Akt(E40K) or detected induction of this 
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system as a readout.  
 Overall, DD-Akt(E40K) presents a valuable tool for in vitro studies requiring dose-
responsive control of Akt signaling. 
 
6.2:  Proof of Principle for Akt-Mediated Inducible Pro-Survival and Trophic Effects 
 In Chapter 4, we used this DD-mediated approach to demonstrate that Akt is capable of 
protecting cells against insults that lead to apoptotic death. This included protection of 
undifferentiated PC12 cells against growth factor removal-mediated death and neuronal cultures 
against PD mimetic neurotoxins, 6-OHDA and MPP+, both in an inducible manner (Chapter 
4.2.2 and Chapter 4.2.3).  
 In Chapter 5, we demonstrated further the capability of DD-Akt(E40K) to induce trophic 
effects in dopaminergic neurons of the SNpc in mice. This finding corroborates previous studies 
demonstrating significant trophic effects on neuronal cell size with the overexpression of 
myristoylated Akt [138].  
 Thus, our work achieves two major accomplishments:  
First, we have validated the downstream physiological effects of Akt(E40K), which has 
been demonstrated to replicate certain Akt functions such as transformation of hematopoietic 
cells and inhibition of apoptosis induced by IL-3 withdrawal [222, 223], but never, to our 
knowledge, inhibition of apoptosis in PD models or trophic effects on neuronal cell size.  
Second, we have provided evidence to further support the legitimacy of targeting Akt 
signaling as a strategy for Parkinson’s disease therapies. Further studies should investigate this 
approach in promoting survival against additional PD models, particularly non-toxin models 
such as in vitro and in vivo α-synuclein fibrils or AAV-delivered α-synuclein overexpression in 
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vivo models [20, 32, 261]. 
 Next steps may also include studies into the role of inducible Akt in neurite restoration, 
as this may open possibilities for DD-Akt(E40K) as a research tool to study this function of Akt 
activity as well as a clinical tool for nerve regeneration in brain disease. 
 
6.3:  Insights into the Clinical Utility of DD-Mediated Control of Akt 
 With continued development of gene therapy techniques as a therapy for Parkinson’s 
disease, the DHFR-derived DD system provides great potential as a gene therapy tool to control 
protein levels within the CNS [262, 263]. The use of TMP as a regulator of this system lends a 
significant advantage to its clinical utility due to its ability to cross the blood brain barrier [215] 
and safety for long-term prophylactic use [216-219]. Thus, one may imagine a future treatment 
where the levels of a therapeutic protein are controlled by oral administration of a safe, approved 
antibiotic. In particular, with Akt dysfunction being implicated in various neurological disorders, 
including Parkinson’s disease, our approach using DD-Akt(E40K) poses a promising therapeutic 
strategy if optimized for regulatability in animals [141, 143-148, 152, 162, 163]. 
In Chapter 5, we presented surprising findings into the contrasting behavior of the DD 
system depending on the target region of expression. More specifically, we identified detectable 
inducibility of DD-Akt(E40K)-Flag in the mouse striatum, but not in the mouse SNpc (Chapter 
5.2.2). This finding is important in that it provides concrete evidence of the limitations on the 
clinical utility of the DD system, particularly its use as a therapeutic strategy for Parkinson’s 
disease if dependent on expression of the system in the SNpc. However, the approach of 
targeting Akt activity as a therapy in Parkinson’s disease may still be viable if further studies are 
done using alternative inducible methods, perhaps based on light-mediated protein stability [207] 
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or tetracycline-controlled inducible systems. 
Furthermore, the potential for DD-mediated inducible Akt as a clinical tool remains 
strong for other diseases involving Akt dysfunction in various other brain regions, including 
other degenerative disorders such as Alzheimer’s disease and prion disease [146-148], or even 
neuropsychiatric and neurodevelopmental disorders such as schizophrenia, autism spectrum 
disorder, epilepsy, and developing brain malformations [143-145]. Additionally, if a 
neurorestorative role of inducible Akt is validated as discussed above, DD-Akt(E40K) presents a 
potential clinical tool to treat diseases involving nerve damage and provide functional restoration 
in patients suffering from these diseases. 
 
6.4:  Insights into Parkinson’s Disease Biology 
Various mechanisms for selective neuronal vulnerability within Parkinson’s disease have 
been explored but research has not been able to conclusively provide an explanation for selective 
degeneration of dopaminergic neurons within the SNpc [264, 265]. Our unexpected findings of 
the lack of apparent TMP-mediated DD-Akt(E40K)-Flag inducibility in the SNpc (Chapter 
5.2.2) suggests an intriguing insight into the biology of Parkinson’s disease with regards to its 
pathogenesis and selective vulnerability of SN dopaminergic neurons.  
With reports of decreased proteasomal activity in the SN [237, 238], our data regarding 
lack of detectable inducibility in the SNpc of mice provide further evidence of decreased 
proteasomal function in the SNpc, even under non-disease contexts. Additionally, our findings 
demonstrate for the first time a concrete functional outcome of reported lower proteasomal 
activity in the SNpc, showing that the putative difference in proteasomal activity between the 
SNpc and striatum is sufficient to interfere with degradation of a protein that we have found to 
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be normally degraded in other cell types within culture (Chapter 3.2.1 and Chapter 5.2.2). This 
conclusion is supported by our in vitro data, showing that the measured DD-Akt(E40K) basal 
levels are greater than 250% higher in dopaminergic neurons than non-dopaminergic neurons 
within the same cultures (Chapter 3.2.2). We believe these results merit further investigation into 
the possibility of lower proteasomal activity within the dopaminergic neurons of the SNpc 
contributing to decreased ability to clear abnormal or misfolded proteins, including α-synuclein, 
and thus leading to the selective degeneration that is a key characteristic of Parkinson’s disease. 
Further studies using basal expression levels of DD-Akt(E40K) as a readout of proteasomal 
degradation may be used to parse out differences in proteasomal activity across different 
neuronal subtypes, both in cell culture and in vivo utilizing viral vectors developed for the studies 
presented here. An intriguing next step would be to determine any differences in proteasomal 
degradation capability in SNpc neurons compared to VTA neurons through midbrain culture 
studies and viral injections of DD-Akt(E40K) in animals.  
 
6.5:  Closing Statement 
 This dissertation establishes a novel approach to control Akt activity, with particular 
emphasis on its utility as therapeutic tool in Parkinson’s disease. We have demonstrated that 
although clinical utility of DD-Akt(E40K) may be limited in the context of Parkinson’s, our 
innovation provides a new tool for the research of Akt signaling and opens new avenues of 
research regarding regional variability of proteasomal degradation and selective vulnerability in 
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